Investigating status of tumorigenic barriers in monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) by ZAHRA KABIRI
 
INVESTIGATING STATUS OF TUMORIGENIC 
BARRIERS IN MONOCLONAL GAMMOPATHY OF 
UNDETERMINED SIGNIFICANCE (MGUS) AND 






























INVESTIGATING STATUS OF TUMORIGENIC 
BARRIERS IN MONOCLONAL GAMMOPATHY OF 
UNDETERMINED SIGNIFICANCE (MGUS) AND 






















A THESIS SUBMITTED  
FOR THE DEGREE OF MASTER OF SIENCE 
DEPARTMENT OF PATHOLOGY 





To my supervisor, A/P Evelyn S.C Koay, I cannot thank her enough for her kindness 
and support. This dissertation has been made possible because of the gracious support 
of her. She has been the most consistent and reliable mentor any student can hope to 
have, and for this, I am immensely grateful. I really appreciate all of kind support and 
advice she gave me as well as the fact that she never seemed to run out of time or 
patience.  
To A/P Chng Wee Joo, I am incredibly grateful for his unfailing guidance, advice and 
expertise. He was a kind and thoughtful advisor, gave me the freedom to develop this 
work, and provided critical feedback throughout the process. I am extremely thankful 
to him for his immense support during my MSc experience. I am fortunate to have 
had the opportunity to work with him. 
To Dr. Ng Siok Bian, for all of her kind help, teaching me IHC interpretation, and 
paying attention and giving me helpful suggestions. It was a great experience working 
with her. 
To Madam Choo Lim Bee, for her great assistance and encouragement. She was very 
nice to me and it was a pleasure to know and work with her. 
To Lee Lee and all of my friends at Special Histopathology Lab and CSI Lab, I learnt 
a lot working with them. They helped me troubleshoot and always kindly support me. 
I’m indebted to them. 
To my family and my parents, Naser and Manijeh, their support compel me to 
accomplish anything. 
And finally, to my husband Hamed, for his patience and staunch stanch support that 




Table of Contents 
Acknowledgement ......................................................................................................... I 
Table of Contents .......................................................................................................... II 
Summary ...................................................................................................................... VI 
List of Tables ............................................................................................................ VIII 
List of Figures .............................................................................................................. IX 
List of Abbreviations ................................................................................................. XII 
Statement of problems encountered during project ................................................... XII 
1. Introduction ................................................................................................................ 1 
1.1 Multiple Myeloma ................................................................................................ 1 
1.1.1 Definition ....................................................................................................... 1 
1.1.2 Epidemiology................................................................................................. 1 
1.1.3 Clinical Manifestation ................................................................................... 2 
1.1.4 Diagnosis ....................................................................................................... 4 
1.1.5 Staging ........................................................................................................... 6 
1.1.6 Treatment ....................................................................................................... 9 
1.1.7 Pathogenesis ................................................................................................ 11 
1.1.8 Genetics ....................................................................................................... 14 
1.2 Monoclonal Gammopathy of Undetermined Significance ................................. 16 
1.2.1 Definition ..................................................................................................... 16 
1.2.2 Prevalence .................................................................................................... 16 
1.2.3 Diagnosis ..................................................................................................... 17 
1.2.4 Pathogenesis ................................................................................................ 20 
1.2.5 Management ................................................................................................ 21 
1.3 Immunohistochemistry (IHC) ............................................................................ 22 
III 
 
1.3.1 Antibodies .................................................................................................... 24 
1.3.2 Fixation ........................................................................................................ 26 
1.3.3 Antigen Retrieval ......................................................................................... 26 
1.3.4 Enzyme Reaction ......................................................................................... 27 
1.3.5 Staining Methods ......................................................................................... 28 
1.3.5.1 Direct staining technique ...................................................................... 28 
1.3.5.2 Two-step indirect technique .................................................................. 29 
1.3.5.3 Avidin-biotin technology (ABC) .......................................................... 30 
1.3.5.4 Chain polymer-conjugated technology ................................................. 31 
1.3.5.5 Envision procedures for the simultaneous staining of several tissue 
markers .............................................................................................................. 32 
1.3.6 Automation in immunehistochemistry ........................................................ 34 
1.3.6.1 Bond-Max stainer .................................................................................. 34 
1.3.6.2 Ventana BenchMark XT ....................................................................... 35 
1.4 Background, Significance and Experimental Design ......................................... 36 
2. Methods & Materials ............................................................................................... 47 
2.1 MM Samples ...................................................................................................... 47 
2.2 IHC single staining ............................................................................................. 48 
2.3 IHC double staining ........................................................................................... 48 
2.4 Single IHC Scoring ............................................................................................ 49 
2.5 Double IHC Scoring ........................................................................................... 49 
2.6 Cut off determination for each marker ............................................................... 50 
2.7 Dewaxing and hydration of tissue ...................................................................... 50 
2.8 Hematoxiline and Eosin Staining (H&E) ........................................................... 50 
2.9 IHC staining ....................................................................................................... 51 
IV 
 
2.9.1 IHC protocol for CD138 (Single staining) .................................................. 51 
2.9.2 IHC protocol for MUM 1 (Single staining) ................................................. 51 
2.9.3 IHC protocol for p53 (Single staining) ........................................................ 52 
2.9.4 IHC protocol for Ki 67 (Single staining) ..................................................... 52 
2.9.5 IHC protocol for Bcl-2 (Single staining) ..................................................... 52 
2.9.6 IHC protocol for CD 20 (Single staining) ................................................... 53 
2.9.7 IHC protocol for p-p53 (Single staining) .................................................... 53 
2.9.8 IHC protocol for p-CHK2 (Single staining) ................................................ 54 
2.9.9 IHC protocol for MDM2 (Single staining) .................................................. 54 
2.10 Double IHC staining in automated stainer ....................................................... 57 
2.11 Statistical analysis ............................................................................................ 57 
2.12 Reagents for single staining IHC ..................................................................... 58 
2.13 Leica Bond-Max reagents ................................................................................ 58 
2.14Ventana BenchMark XT reagents ..................................................................... 58 
3. Results ...................................................................................................................... 61 
3.1 Evaluation of p53 expression ............................................................................. 61 
3.1.1Staining pattern ............................................................................................. 61 
3.1.2 p53 expression in MGUS and MM ............................................................. 61 
3.2 Evaluation of Bax and Bcl-2 expression ............................................................ 63 
3.2.1 Staining pattern of Bax ................................................................................ 63 
3.2.2 Staining pattern of Bcl-2.............................................................................. 66 
3.2.3 Bax and Bcl-2 expression in MGUS and MM patients ............................... 68 
3.3 Evaluation of Ki67 and Cycline D1 expression ................................................. 70 
3.3.1 Staining pattern of Ki67 .............................................................................. 70 
3.3.2 Staining pattern of Cyclin D1 ...................................................................... 73 
V 
 
3.3.3 Cyclin D1 and Ki7 expression in MM and MGUS ..................................... 75 
3.4 Evaluation of p16 and cleaved caspase 3 (CC3) expression .............................. 77 
3.4.1 Staining pattern ............................................................................................ 77 
3.4.2 p16 expression in MGUS and MM ............................................................. 81 
3.4.3 Cleaved Caspase 3 expression in MM and MGUS ..................................... 81 
4. Discussion ................................................................................................................ 83 
4.1 DDR and OIS barriers in MGUS and MM ........................................................ 83 
4.2 Individual marker evaluation in MM and MGUS .............................................. 86 
4.2.1 p53 expression ............................................................................................. 86 
4.2.2 Bax and Bcl-2 expressions .......................................................................... 87 
4.2.3 Cleaved Caspase 3 expression ..................................................................... 90 
4.2.4 p16 expression ............................................................................................. 92 
4.2.5 Cyclin D1 and Ki67 expressions ................................................................. 93 
5. Conclusion ............................................................................................................... 97 











Multiple myeloma (MM), an incurable late stage B-cell malignancy characterized by 
the presence of monoclonal plasma cells in the bone marrow, is the second most 
common haematological malignancy after non-Hodgkin’s lymphoma. It is mostly 
preceded by the pre-malignant tumor stage, monoclonal gammopathy of 
undetermined significance (MGUS). MGUS progresses sporadically to MM with a 
probability of about 0.6-3% per year. Until now, all the disease-initiating genetic 
abnormalities are found in MGUS at a similar frequency as in MM. Thus, the genetic 
abnormalities causing the transformation of MGUS to MM are still unknown. Recent 
studies have shown that two important tumorigenic barriers, DNA damage response 
(DDR) and oncogene-induced senescence (OIS), are activated in various premalignant 
tumors, and malignant transformation is accompanied by defects in these barriers. The 
aim of my thesis project is to study whether defects in one or both of these barriers 
might also mediate transformation from MGUS to MM.  
Double staining IHC method was optimized and applied to compare the differential 
status of DDR checkpoint and OIS between MM and MGUS. As activation of DDR 
and OIS give rise to senescence or apoptosis in cells, different markers of cell cycle 
checkpoint, proliferation, apoptosis, and senescence such as Cyclin D1, Ki67, p53, 
Bax, Bcl-2, CC3, and p16 were combined with CD138 as plasma cell markers and 
optimized in the Ventana automated stainer (Roche). The double staining IHC was 
important in determining the pattern of expression of these specific markers in the 
bone marrow plasma cells, as CD138 stained the membrane of the plasma cells whilst 
the other markers had either cytoplasmic or nuclear staining. 
Our results showed that CC3 expression as a phenotypic marker of apoptosis was 
significantly (p-value=0.03) increased in MM compared to MGUS samples. However, 
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we did not see overexpression of the apoptosis and senescence markers in MGUS 
compared to MM. For example, p16 expression as a senescence marker did not 
change in both groups (p-value=0.09). Due to failure to find primary evidence of 
DDR or OIS activation in MGUS, we are not able to suggest that defects in OIS or 
DDR causes transformation of MGUS to MM, based on our work thus far.  
Furthermore, Bax and Bcl-2 overexpression was observed in MM samples compared 
to MGUS (Bax p-value=0.001, Bcl-2 p-value<0.001). Whilst Bcl-2 overexpression 
was also associated with short overall survival (log-rank p-value=0.04) in our MM 
patients, Bax overexpression was not similarly associated (log-rank p-value=0.46). 
Expression of Cyclin D1, Ki67, p53 did not vary between MGUS and MM samples 
(p-values were 1, 0.18, and 0.10, respectively). Neither was overall survival of MM 
patients associated with expression of Cyclin D1, Ki67, p16, and CC3. In contrast, 
p53 expression showed significant association with poor prognosis (lon-rank p-
value=0.003).  
In conclusion, increased levels of pro- and anti-apoptotic markers were found in MM 
compared to MGUS patients; however, the senescence and proliferation markers were 
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Statement of problems encountered during the project 
(1) Prior to coming to Singapore to begin my M.Sc. program, I started to collect bone 
marrow biopsy BMB of myeloma patients from Iran to add to the Singaporean sample 
pool for my proposed thesis project, after consulting with my supervisor. Collecting 
the clinical data and BMB of 80 myeloma patients prospectively in different hospitals 
and pathology laboratories took 4 months, since there were no appropriate paraffin-
embedded archival tissues in Iran to meet with my requirements. The 1200 sections 
were cut and transferred to Singapore, because we did not have permission to export 
the BMBs to Singapore.  However, after preliminary trials, I found that these 
myeloma samples were not usable for this project as the quality of paraffin embedded 
tissues was not good for double staining immunohistochemistry (IHC) work. Indeed, 
the calcification of bone marrow samples and fixation process carried out at the 
Iranian histology laboratories were not done well.  
(2) In 2008 when I commenced the IHC bench work the selection and optimization of 
various markers such as p53, p-p53, p-CHK2, ki67, Bcl-2, CD20, and MDM2 were 
done in six months and all markers were applied for single IHC staining in myeloma 
and MGUS samples. Unfortunately, we experienced a lot of problems to score any of 
the above-mentioned markers, since bone marrow has different cells and 
identification of plasma cells by morphology is not accurate method. In particular, the 
scoring of the MGUS samples was exceedingly difficult, because there are very few 
plasma cells in the bone marrow of MGUS patients. Thus, we decided to optimize the 
double staining protocol for some markers, but we were not able to do double staining 
without an autostainer. Finally, the Department of Pathology had a BondMax 
autostainer installed and we were then able to begin optimization of p53/CD138, 
Ki67/CD138, Bcl-2/CD138, CD20/CD138, and MDM2/CD138 in a few bone marrow 
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samples. With some initial success with the double-staining protocols, we 
subsequently bought reagents for the double staining IHC for 600 tests. 
Unfortunately, the specific new red kit which we acquired did not work properly and 
some of the bone marrow cells were not stained for red color. As the vendor had 
stopped production of the old kit, and were not able to resolve the problem of 
inadequate staining by the new replacement kit, we ended up losing 5 more months, 
which was the time taken to perform the  optimization of various markers on the 
Bond-Max stainer. 
(3) Following the failure with the Bond-Max staining protocols, we started to 
optimize markers on the Ventana autostainer, which we found to be a more suitable 
stainer for double staining IHC of our selected markers. We proceeded to optimize 
double staining for various markers including p-p53, p53, p-CHK2, DCR2, p21, p16, 
Ki67, Bax, Bcl-2, CD20, MDM2, Cyclin D1, and CC3. But, due to constraints of time 
(I only had a two-year scholarship contract provided by A-STAR, which ends in 
January 2010), we were just able to optimize some of the above, namely, p53/CD138, 
Ki67/CD138, Cyclin D1/CD138, p16/CD138, Bax/CD138, and CC3/CD138 markers. 
In conclusion, our results included in my thesis write-up are based on double staining 
IHC performed on the Ventana stainer only. I did not include the results of the single 
staining for p-p53 and p-CHK2 in this thesis; however, the expressions of these two 








1.1 Multiple Myeloma  
1.1.1 Definition 
Multiple myeloma (MM) is a plasma cell malignancy that is derived from a single 
clone and distributed at several sites of bone marrow. In many cases, it is preceded by 
a pre-malignant tumor stage, monoclonal gammopathy of undetermined significance 
(MGUS), which is the most frequent lymphoid tumor in humans. 
The elevated production of monoclonal antibodies and bone disruptions are two 
prominent features of MM. The host response to plasma cell infiltration into different 
organs also leads to multiple organ dysfunctions and symptoms of renal failure, 
hypercalcemia, anemia, hyperviscosity, susceptibility to infections, bone pain or 
fractures, and neurological symptoms [1]. 
 
1.1.2 Epidemiology 
Multiple myeloma is an incurable cancer with a prevalence of 20,000 new cases per 
year in the United States. This is the second most common hematological malignancy 
after non-Hodgkin’s lymphoma (NHL) and accounts for approximately 1% of 
neoplastic diseases and 13% of hematological cancers.  The incidence differs globally 
from 1 case per 100,000 people in China, to about 4 cases per 100,000 people in the 
developed countries. In addition, the incidence adjusted for gender and race is 7-10 
per 100,000 in men and 4-6 per 100,000 in women, and it is two times higher in black 
Americans than white Americans. In Singapore, the prevalence of MM was reported 
as 0.6% in men and 0.5% in women from 1998 to 2002. Also, the risks for Malay 
females and Indian males were slightly higher than for Chinese [2].  
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 There is no known reason for this unequal sex and race distribution. This malignancy 
is a disease of the elderly, with the age range of 20-92 years and the median age of 62 
and 61 years in men and women respectively; with only 2% of patients being younger 
than 40 years old [3,4]. 
MM accounts for almost 20% of deaths from hematological malignancies and 
approximately 2% of deaths from cancers. Depending on different treatments, the 
survival rate varies from 3 to 7 years, for example, after conventional treatment the 
median survival is about 3 to 4 years. However, high dose chemotherapy treatment 
plus autologous bone marrow transplantation (BMT) can extend the median survival 
of MM patients by 5 to7 years [5,6]. 
 
1.1.3 Clinical Manifestation 
Bone pain is the most common symptom in MM and affects the quality of life 
adversely in approximately 70% of the patients. Bone pain is precipitated by 
movement and typically involves the ribs and the backbone. The lytic bone lesions are 
caused by proliferation of plasma cells in bone, activation of osteoclasts and 
suppression of osteoblasts. In myeloma patients, the localized and persistent pain 
often indicate frequency of pathologic fracture [7]. 
The next common clinical manifestation is bacterial infection, which is often the 
major cause of death in these patients. The lung and urinary tract are the most 
susceptible organs to infections. Streptococcus pneumoniae, Klebsiella pneumoniae, 
and Staphylococcus aureus are common pathogens in the lung and Escherichia 




Around 20-40% of newly diagnosed patients have renal failure. This complication is 
generally caused by the cytotoxic effects of monoclonal light chain deposition in the 
renal anatomical structure, primarily in the tubules and to a lower extent the 
glomeruli. Other contributory factors include hypercalcemia, dehydration, and use of 
nephrotoxic drugs, contrast agents, and occasional infiltration of the kidney by plasma 
cells [9]. 
Approximately 20-60 % of patients have mild to moderate anemia at the time of 
diagnosis and almost all patients with uncontrolled disease become anemic. The 
anemia in MM patients is a normocytic, normochromic anemia due to replacement of 
BM hematopoietic cells by plasma cells and inhibition of haematopoiesis by tumor 
factors. Megaloblastic anemia is also present in some patients due to vitamin B12 or 
folate deficiency  [10]. 
Another clinical feature of myeloma is the accompanying clotting abnormalities. This 
is caused by failure of antibody-coated platelets to function appropriately or 
interaction of the M-protein with clotting factors. MM patients are at risk of 
developing deep venous thrombosis (DVT), especially when receiving lenalidomide 
or thalidomide chemotherapy, in combination with dexamethasone.  
The neurologic symptoms that occasionally occur in MM patients have many causes. 
Hyperviscosity may cause fatigue, headache, visual disturbances, and retinopathy. 
Hypercalcemia may produce lethargy, depression, weakness, and confusion. Bone 
damage may lead to cord compression, and loss of bladder and bowel control. 
Amyloid infiltration in peripheral nerves can cause sensory motor neuropathies such 
as carpal tunnel syndrome. In addition, sensory neuropathy can be a side effect of 




MM is diagnosed based on three criteria:  
1- Monoclonal plasma infiltration (CD138+) cell into the bone marrow, which is 
assessed in bone marrow aspiration (BMA) or bone marrow biopsy (BMB).  
2- Presence of M-protein in serum or urine, detected by immunofixation and 
electrophoresis.  
3- Bone lytic lesions, screened by MRI and skeletal survey. 
The most common differential diagnosis in myeloma patients is monoclonal 
gammopathy of undetermined significance (MGUS). MGUS can be distinguished 
from myeloma by an M-protein level of 0.5 to 3 g/dL, with less than 10% plasma cell 
in bone marrow [4]. 
The second differential diagnosis in myeloma patients is smoldering multiple 
myeloma (SMM), which contains 10-30% plasma cell infiltration in bone marrow 
without osteolytic lesions or any other secondary manifestations of symptomatic 
myeloma, and an M-protein level ≥3 g/dL. However, symptomatic MM patients also 
present with more than 10% monoclonal plasma cells in their bone marrow, an M-
protein level of ≥3 g/dL in serum or urine, and presence of end organ damages such as 
osteolytic bone lesion, renal failure, and other secondary manifestations of 
myeloma(Table 1)  [1].  
Exteramedullary MM involves extramedullary sites of the bone marrow such as skin, 
pleural fluid, and blood. It is an aggressive malignancy, and when involving the blood 







Table 1: Diagnostic criteria for multiple myeloma and monoclonal gammopathy 
of undetermined significance 
 
Monoclonal gammopathy of undetermined significance (MGUS) 
M protein in serum <30 g/L 
Bone marrow clonal plasma cells <10% 
No evidence of other B cell proliferative disorders 
No myeloma-related organ or tissue impairment (no end organ damage, 
including bone lesions) 
Asymptomatic myeloma (smouldering myeloma) 
M protein in serum >30 g/L and/or 
Bone marrow clonal plasma cells >10% 
No myeloma-related organ or tissue impairment (no end organ damage, 
including bone lesions) or symptoms 
Symptomatic multiple myeloma 
M protein in serum and/or urine 
Bone marrow (clonal) plasma cells or plasmacytoma 








Figure 1: Staging of multiple myeloma a) MM arises from a normal germinal center 
of B-cell. Around 30% of MM seems to arise from MGUS without passing through 
SMM. The intramedullary myeloma is just localized in bone marrow, but with time 
the tumor can acquire the ability to invade extramedullay locations (skin, blood, and 
pleural fluid) and develops the extramedullary myeloma. Also, most MM cell lines 
are derived from extramedullary myeloma. b) The low proliferative index in MGUS. 
IHC staining for ki67 and CD138. c) Bone marrow staining of CD34 to show an 
increase vascularity in MM. d) Punched-out bone lesions in MM. e) Peripheral blood 
smear with plasma cells circulating in Plasma cell leukemia. Adapted from Kuehl 
WM, Bergsagel PL: Multiple myeloma: evolving genetic events and host interactions. 
Nat Rev Cancer 2002, 2(3):175-187, with modification.  
 
1.1.5 Staging 
There are multiple staging systems for predicting the survival of myeloma patients 
based on clinical data and laboratory tests. The first popular system introduced by 
Durie and Salmon in 1975 was based on various factors such as level and type of 
7 
 
monoclonal protein (M-protein), calcium level, hemoglobin, and number of bone 
lesions. The Durie and Salmon (DS) staging has three stages (I, II, III) and each stage 
is subdivided in two substages based on renal function (A: serum creatinine less than 
2 mg/dL and B: serum creatinine more than 2 mg/dL).  Median survival for patients in 
stage IA is more than 5 years and for stage IIIB is about 15 months (Table 2). 
However, emerging novel targeted therapies and high dose chemotherapies in 
myeloma treatment made the DS staging system less applicable. An additional 
detracting factor   is the number of lytic lesions, an important factor in DS staging, is 
observer dependent. Therefore, the international staging system (ISS) was proposed to 
overcome the limitation of DS staging. 
ISS, the most powerful and reproducible classification in myeloma, is based on serum 
β2microglobulin (β2M) and albumin levels, which make it as a simple system with 
widespread use.  The ISS consists of three stages: Stage I (β2M less than 3.5 mg/L 
and serum albumin ≥3.5 g/dL with median survival of 62 months), Stage II (neither 
stage I nor III with median survival of 44 months), and stage III (β2M≥ 5.5 mg/L with 
















burden, × 1012 
cells/m2  
I All of the following:  
 
1. Hemoglobin >100 g/L (>10 
g/dL) 
2. Serum calcium <3 mmol/L 
(<12 mg/dL) 
3. Normal bone x-ray or solitary 
lesion 
4. Low M-component production 
a. IgG level <50 g/L (<5 
g/dL) 
b. IgA level <30 g/L (<3 
g/dL) 
c. Urine light chain <4 
g/24h 
<0.6 (low) 
II Fitting neither I nor III 0.6-1.20 (intermediate) 
III 
One or more of the following: 
1. Hemoglobin <85 g/L (<8.5 
g/dL) 
2. Serum calcium >3 mmol/L 
(>12 mg/dL) 
3. Advanced lytic bone lesions 
4. High M-component 
production 
a. IgG level >70 g/L (>7 
g/dL) 
b. IgA level >50 g/L (>5 
g/dL) 




Level Stage Median survival, months 
Subclassification based on serum creatinine levels 
A<177 µmol/L (<2 
mg/dL) IA 61 
B>177 µmol/L (<2 
mg/dL) IIA, B 55 
 IIIA 30 




Table 3: International staging system 
Level Stage Median survival, months 
β2M<3.5, alb≥3.5 I (28%) 62 
β2M<3.5, alb<3.5 or β2M=3.5-
5.5 
II (39%) 44 
β2M>5.5 III(33%) 29 
 
*Note: β2M, serum β2-microglobulin in mg/L; alb, serum albumin in g/dL; (#), % 




Smoldering multiple myeloma (SMM) and MGUS do not require any treatment. 
However, symptomatic or progressive myeloma needs therapeutic intervention, which 
can significantly improve the quality of life and also prolong survival of patients. 
Myeloma treatments are based on systemic therapy and symptomatic supportive care 
to control the progression of MM and prevent severe morbidity from the MM 
complications, respectively.      
The initial standard therapy for newly diagnosed patients is based on whether or not 
the patient is a candidate for autologous stem cell transplantation (ASCT) plus high 
dose chemotherapy.  In transplant candidate, melphalan should be avoided as it will 
damage stem cells. High-dose pulsed glucocorticoids alone or in combination VAD 
chemotherapy (vincristine, doxorubicin, dexamethasone) have been used for 
cytoreduction in newly diagnosed patients. In addition, a combination of novel agents 
such as thalidomide, lenalidomide, and Bortezomib with dexamethasone has rapid 
responses in transplant candidates [14].  
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In patients older than 65 years and those who are not transplant candidates, the 
melphalan and prednisone (MP) alone or in combination with thalidomide (MPT) are 
the standard therapies. 
By conventional therapy, the complete response (CR) rate was very low in myeloma 
patients, but introduction of high-dose therapy (HDT) with ASCT increased the 
partial response as well as the CR rate, which led to a prolonged progression-free 
survival in patients. Moreover, two consecutive HTDs (with tandem ASCT) are more 
effective than a single HTD (transplant) in myeloma patients who do not achieve a 
good partial response or complete response [15]. 
Novel agents in myeloma treatment such as lenalidomide, bortozemib, and liposomal 
doxorubicin, which are effective on tumor cells and bone marrow stromal cells, can 
be used to treat the relapsed/refractory myeloma patients. In addition, thalidomide can 
achieve good responses in refractory cases if it is not used as initial therapy [16]. 
Supportive care of complications in myeloma are as important as primary anti-tumor 
treatments. For instance, the hypercalcemia responds well to Bisphosphonates, 
hydration, and glucocorticoids therapy. The gold standard of hyperviscosity syndrome 
is plasmapheresis. Since myeloma patients are immune deficient and at risk of 
infections, it is really important to control the lung and urinary tract infections by 
vaccination, prophylactic IV immunoglobulin and aggressive treatments. Supportive 
treatments of bone fractures, pain, fatigue, anemia, and emotional distress as well as 
treatment of renal failure are critical parts of the therapeutic management of MM 





MM is a malignancy of incompletely differentiated plasma cells. But, the relationship 
between normal plasma cell and malignant plasma cell has not been identified yet, as 
the normal physiological plasma cell differentiation is a complex and multi-step 
process.  
B-cells follow three optional fates after activation by antigens: elimination by 
apoptosis due to self-reactivity or low affinity, differentiation to memory B-cells 
following affinity maturation or terminal differentiation to immunoglobulin secreting 
plasma cells. Memory B-cells are long-lived cells, their activation by antigens leads to 
rapid antibody response. Plasma and memory B-cells are arrested in G1 phases of the 
cell cycle, prompts an important question of how the cell fate and divergent 
differentiation control the cell cycle [16]. 
Plasma cells are important for the antibody response as they produce large numbers of 
immunoglobulins (Igs), which are specific for antigens.  In addition to Igs, the CD138 
(Syndecan-1) is the only protein that increases on the surface of plasma cells during 
the early stages of differentiation and is an excellent marker for plasma cell 
identification. CD138 also presents in malignant plasma cells and its function has not 
been identified in normal and malignant plasma cells yet. Through homeostasis of 
plasma cells, primary plasma cells are not able to divide and they are arrested in the 
G1 phase of the cell cycle. These plasma cells are eliminated by apoptosis following 
Ig secretion. But, certain long-lived plasma cell populations in lamina propria of 
intestines and bone marrow are exempted from apoptotic elimination and they provide 
long-term immunity in the body. Consequently, these long-lived plasma cells are 
more relevant to the development of malignant myeloma cells, which also accumulate 
in the bone marrow [17].  
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Plasma cell differentiation occurs in the extra-follicular foci, because the activated B-
cell leaves the germinal center (GC). Post-germinal center or germinal center B-cells 
have modified their immunoglobulin (Ig) genes by IgH switch recombination, 
sequential rounds of somatic hypermutation, and also antigen selection. Two specific 
DNA modifications can cause double strand DNA breaks or mutations near non-Ig 
genes and oncogenes in (GC) B-cells (Figure 2)  [12]. Furthermore, the post-germinal 
center B-cells can produce plasma blasts (PBs) that have successfully finished 
somatic hypermutation, antigen selection, and also IgH switching before moving  to 
the bone marrow , where stromal cells facilitate the plasma blast terminal 
differentiation into long-lived Plasma Cells (PCs).  
The origin of long-lived and short-lived plasma cells and how they migrate to bone 
marrow are still mysterious. Moreover, better understanding of myeloma pathogenesis 
depends on complete explanation of plasma cell differentiation process. Therefore, 
more studies are needed to answer the underlying mechanisms of plasma cell 







Figure 2: B-cell development. The VDJ recombination, somatic hypermutation and 
Ig heavy chain (IgH) switch recombination are three B-cell-specific DNA remodelling 
mechanisms. Sequential and regulated VDJ recombination assembles combinations of 
the many Ig V, D and J segments in precursor bone-marrow B-cells to create Ig heavy 
chain (H)/Ig light chain (L) antigen receptors. After VDJ recombination step, 
immature B-cells that express functional surface IgM exit the bone marrow and home 
to secondary lymphoid tissues as mature B-cells.  
Productive interaction of mature B-cells with antigen results in proliferation and 
differentiation. Indeed, the primary immune response generates pre-germinal-center 
plasma cells that typically are short lived, and usually secrete IgM but can secrete 
other Igs as a result of IgH switch recombination. 
Germinal centres are generated during the primary immune response. Antigen-
activated lymphoblasts that enter a germinal centre are subjected to multiple rounds of 
somatic hypermutation of IgH and IgL V(D)J sequences and antigen selection. Cells 
that express high-affinity antigen receptors are selected for survival, with subsequent 
differentiation to memory B cells or post-germinal-centre plasma cells. Then, post-
germinal-centre plasmablasts/plasma cells that undergo IgH switch recombination 
typically home to the bone marrow. Adapted from Kuehl WM, Bergsagel PL: Multiple 
myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002, 




The majority of recent myeloma studies focus on the genetic events driving the 
pathogenesis of myeloma disease. Fluorescence in-situ hybridization (FISH) and 
cytogenetics have confirmed numerous abnormalities that involve the genes of the 
myeloma cells leading to both hyperdiploid and non-hyperdiploid patterns. 
Hyperdiploid abnormalities, caused by several trisomies (3, 5, 7, 9, 11, 15, 19, and 
21), are associated with better outcome compared to non-hyperdiploid abnormalities 
that are associated with reduced life span because of partial loss of chromosome 17 
(p13) and high risk translocations of chromosome 13.  There are several recurrent IgH 
translocations that are presented in the primary oncogenic events and early 
pathogenesis of MM. These primary translocations most frequently happen at IGHR 
on chromosome 14 (q23.33), which is typically juxtaposed to MAF 
(t[14;16][q32.33;23]), CCND1 (t[11;14][q13;q32.33]), CCND3 (t[6;14][p21;q32.33]), 
FGFR3 and WHSC1 (t[4;14][p16.3;q32.33]), and MAFB t[14;20] [q32.33;q11.1]) [4]. 
The secondary translocation abnormalities that have caused disease progression are 
complex abnormalities of MYC, secondary Ig translocations, FGFR3 mutations, 
inactivation of RB1, TP53, and PTEN by mutations or deletions, activation of NRAS, KRAS, 





   
 
 
Figure 3: Disease stages and timing of oncogenic events. The earliest oncogenic 
changes are present in monoclonal gammopathy of undetermined significance 
(MGUS) and involve two minimally overlapping pathways, primary IgH 
translocations and multiple trisomies, each of which can include a del 13 pathway. 
Other karyotypic abnormalities, including secondary (Ig) TLC, and epigenetic 
changes can occur at all stages. Activating mutations of K- or N-RAS appear to mark, 
if not cause, the MGUS to multiple myeloma (MM) transition in some cases, but 
sometimes occur during subsequent progression of MM. Late oncogenic events that 
occur at a time when tumors are becoming more aggressive include MYC 
dysregulation by secondary (Ig) TLC, bi-allelic deletion of p18, inactivation of Rb, 
and loss or mutation of p53. Adapted from Kuehl WM, Bergsagel PL: Early genetic 
events provide the basis for a clinical classification of multiple myeloma. Hematology 







1.2 Monoclonal Gammopathy of Undetermined Significance 
1.2.1 Definition 
The term, monoclonal gammopathy of undetermined significance (MGUS), indicates 
the existence of a monoclonal protein (immunoglobulin or M-protein) in serum of 
individuals without the clinical features of primary amyloidosis (AL), Waldenström's 
macroglobulinemia (WM), and multiple myeloma (MM) or other plasma cell 
disorders. MGUS patients have a serum M- protein concentration of less than 3 g/dL, 
and the proportion of plasma cells in bone marrow less than 10%, with no clinical 
manifestations associated to their monoclonal gammopathy [18]. 
The term MGUS was first established in 1978 and replaced other terms such as 
benign or idiopathic monoclonal gammopathy and essential hyperglobulinemia. 
Monoclonal gammopathy cannot be considered as a benign disease, because a 
comprehensive study, which was done by Dr. Robert Kyle in 241 MGUS patients 
from the Mayo Clinic (Rochester, MN, USA) series in 1978, showed that a large 
number of these patients eventually progress to malignant disorders. Indeed, MGUS is 
an asymptomatic pre-malignant plasma cell disorder with high chance of progression 
to MM or other plasma cell dyscrasia with the passage of time [19]. 
 
1.2.2 Prevalence 
The prevalence of MGUS is generally related to age, ethnic descent, and/ or race. The 
incidence of MGUS increases in the elderly, with the median age of 70 years at 
diagnostic time. Some studies showed that the prevalence rate is around 1% and 3% 
for individuals over the age of 50 and 70 years, respectively. In addition, the 
prevalence of MGUS has been reported to be two or three times higher in blacks 
compared with whites. For example, a study of four million white and African–
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American (AA) people whom admitted to Veterans’ Affairs hospitals in the USA showed 
that the incidence of MGUS was threefold higher in Blacks compared to whites. [20] 
As the incidence of MM is also twofold higher in Blacks, it can support the 
hypothesis that the high prevalence of MM in black population is probably due to an 
increased incidence of MGUS in blacks, rather than higher rate of MGUS 
transformation to MM [18]. 
Moreover, the prevalence of MGUS is low (2.4%) in Asia, which has been confirmed by a 
large study of atomic bomb survivors in Nagasaki of Japan. Table.4 shows the prevalence of 
MGUS across the world [21]. 
 
Table 4: Prevalence of MGUS across different countries 
 
Study population Subjects (n) Age (years) Prevalence (%) 
Accra, Ghana 917 50-74 5.8 
Olmsted county, MN, USA 21462 50 3.2 
Provincial hospital, Italy 35005 11-75 2.9 
Nagasaki city, Japan 62802 44-70 2.4 
Finistere, France 30729 50 1.7 
New York, NY, USA 73630 - 1.2 
Varmland, Sweden 6995 25 0.9 
Rangiora, New Zealand 2192 21 0.7 





MGUS is always diagnosed by a homogeneous spike in serum protein electrophoresis 
during routine blood test and it is an incidental finding through evaluation of other 
medical problems. As we mentioned, MGUS patients have serum M-protein level of 
less than 3 g/dL, less than 10% of bone marrow plasma cells, and also they do not 
have any clinical manifestations of plasma cell dyscrasia. Thus, their physical 
examinations are usually normal. 
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The most common diagnostic test is serum protein electrophoresis to determine a 
monoclonal protein. All MGUS patients with serum M-protein greater than 1.5 g/dL 
should do urine analysis as well. The urine electrophoresis is a useful method to 
measure the amount of M-protein in the urine, which is a guide of patient’s mass and 
is helpful in monitoring the course of disease (Figure 4, 5).  
In addition, serum or urine immunofixation is an essential, sensitive and rapid method 
to identify immunoglobulin class and light chain type in all monoclonal 
gammopathies (Figure 6) [22].  
 
 
Figure 4: Pattern of serum monoclonal protein. Top) densitometer tracing after  
electrophoresis on agarose gel showing tall narrow-based peak of γ mobility. Bottom) 
electrophoresis of serum on agarose gel. Anode at left shows dense and the localized 
band in the right is the γ area. Adapted from Kyle RA, Rajkumar SV: Monoclonal 
gammopathies of undetermined significance: a review. Immunol Rev 2003, 194:112-




Figure 5: Polyclonal pattern from densitometer tracing of agarose gel, showing 
broad-based peak of γ mobility. Bottom) polyclonal pattern from electrophoresis of 
agarose gel (anode on left). Band on the right is broad and expand throughout the γ 
area. Adapted from Kyle RA, Rajkumar SV: Monoclonal gammopathies of 






Figure 6: Immunofixation of serum with antisera to IgM, IgG, IgA, κ, and λ shows a 
dense band with IgA and κ, indicating an IgA- κ monoclonal protein. Adapted from 
Kyle RA, Rajkumar SV: Monoclonal gammopathies of undetermined significance: a 





1.2.4 Pathogenesis  
MGUS are characterized by an increased level of monoclonal protein in serum or 
urine, which is caused by a rearrangement of immunoglobulin genes. It is important to 
know that a plasma cell clone has to be relatively large to produce a significant M 
spike at serum and urine electrophoresis. This large plasma cell clone generally 
remains stable for many years in MGUS patients. But, there is approximately 1% 
chance per year that this plasma cell clone develops into a systematic monoclonal 
gammopathy in patients, and then the MGUS state represents a pre-malignant phase 
in these patients. In fact, progression of MGUS to malignant plasma cell dyscrasia 
occurs by a plasma cell clone escaping from regulatory mechanisms that had 
restricted tumor growth for years [23]. 
The pathogenesis of MGUS is not known yet. However, it has been shown that half of 
the patients have primary IgH translocations that can be the early immortalizing 
events. Also, it is interesting that roughly all the MM genetic alternations such as 
chromosome 13q deletion, aneuploidy or translocation t(4;14) are present in many 
MGUS patients. Moreover, Brousseau M et al. found that MGUS and MM patients 
had an equivalent and high frequency of hyperdiploidy, whereas hypodiploidy was 
rare in MGUS. They also showed that deletion of chromosome 13q was always 
observed in hyperdiploid MGUS [24]. Tumor necrosis factor α and interleukin 6 (IL 
6) have also been believed to be involved in pathogenesis of MGUS. On the other 
hand, these two cytokines were not related to progression of MGUS to malignant 
disorders.  
  Many above-mentioned genetic abnormalities observed in MGUS are early events in 
assembling of plasma cell clone and the pathogenesis, but they are not associated with 
progression of MGUS to MM. Indeed, the molecular basis of MGUS progression to 
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malignant gammopathies remains unknown. However, it has been recommended that 
one or more oncogenic events may promote genomic instability in MGUS and result 
in malignant transformation. 
 Based on recent studies, the bone marrow stromal cells might play an important role 
in transformation of MGUS to MM. In support of this hypothesis, it has been shown 
that bone marrow angiogenesis is significantly higher in symptomatic MM compared 
to MGUS, which may explain the role of angiogenesis in MGUS progression. 
Unfortunately, serial follow-up studies to show angiogenesis as a determinant factor 
in MGUS progression have not yet been accomplished. The immune-mediated 
conditions may also play an important role in progression and pathogenesis of MGUS 
and MM [25,26]. 
In conclusion, it is not clear what kind of cellular barriers control plasma cell growth 
in MGUS state for a long time and how these barriers break through progression to 
malignant plasma cell dyscrasia. Knowing the MGUS transformation events enhances 
understanding of MM pathogenesis, and perhaps results to develop the novel targeting 
therapies for treatment of MM patients as well as MGUS patients at high risk of 
progression.  
 
1.2.5 Management  
MGUS patients do not need any clinical interventions or treatments, but they should 
be followed up. Currently, there is no formal guideline to follow up the MGUS 
patients. However, physicians annually re-evaluate MGUS patients to determine 
Multiple Myeloma or other malignant gammopathies before complications. The 
follow up tests are including serum and urine protein electrophoresis, hemoglobin 
level as well as calcium concentration and serum creatinine.  
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The low risk MGUS patients (with M-protein level less than 1.5 g/dL, IgG type, and 
normal free light chain ratio) may not be followed up as the risk of malignant 
progression is very low. On the other hand, the high risk patients (M-protein greater 
than 1.5 g/dL, non-IgG type and an abnormal free light chain) should follow up every 
year, because they have nearly 60% chance to develop the malignant transformation 
during 20 years [18]. 
 
1.3 Immunohistochemistry (IHC) 
The power and usefulness of immunohistochemistry (IHC) are measured by its 
continued successful use for years. The IHC protocols today are more or less the same 
as those protocols used 30 years ago. In this technique, a primary antibody is applied 
to tissue sections or cells to detect a target antigen by applying a detection system and 
also a visualization reagent (enzyme or fluorochrome). This antigen might be a 
protein, a lipoprotein, a glycoprotein, or even a carbohydrate.   
Recently, IHC is being widely used as a diagnostic tool for detecting the presence or 
absence of specific proteins and certain carbohydrates in fixed and embedded tissue 
specimens. It is cheap, easy to perform and can help visualize cell types. The power of 
this technique originates from the great specificity of monoclonal antibodies for 
certain antigen epitopes. In general, this antibody detection system can provide 
valuable information based on location of normal and abnormal genes products 
(between different cell types or inside cellular compartments), and  on the gene 
expression level of  such products in malignant cells compared with normal cells. 
Indeed, IHC links the molecular biology of any cancer with its histological 
characteristics and behavior. In the light of abovementioned advantages, IHC has 
remained as the most popular method in the diagnosis of cancer.   
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Moreover, several reasons justify the efficacy of IHC in the field of surgical 
pathology. For example, this method facilitates the detection and localization of 
particular molecular components in cells. Furthermore, this technique has an excellent 
sensitivity and specificity and can be performed on chemically fixed cells, frozen 
cells, and archival tissues. In addition, routine IHC is quite easy to carry out in any 
laboratory and has been also automated. Other staining techniques do not have these 
advantages.  
However, every method has its own limitations and IHC is not exempt from this fact. 
Many factors can influence staining results, which is causing a high level of 
interalaboratory variability in the IHC results. For example, it is applied to a large 
variety of tissues with different processing ways, involving some important steps with 
each step having potential to affect the final results. IHC is an operator-dependent 
method which is another limitation for this technique. Also, diverse results differed by 
identical antigens could be due to several factors including the use of various 
reagents, detection systems, and antigen retrieval methods. Moreover, the amount of 
antigen degradation or masking depends on the time of intraoperative anoxia, 
temperature and duration of fixation, the type of fixative, quantity and pH of fixative 
used, type of buffer, and penetration of fixative into entire tissue sample. To improve 
the reliability of the IHC technique, processing conditions should be optimized for 
each test.  
During the evolution of IHC, a lot of efforts have been made to improve sensitivity 
for detection of antigens in the formalin-fixed and paraffin-embedded tissues. Several 
strategies are eventually being evaluated for increasing the sensitivity including use of 
direct peroxidise conjugates, avidin-biotin complex (ABC), peroxidise-anti-
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The key reagent common to all immunohistochemical methods is antibody. 
Antibodies belong to a group of proteins named immunoglobulins (Igs). The 
immunoglobulins have five major classes: IgM, IgA, IgE, IgG, and IgD.  Each 
immunoglobulin has two identical heavy chains (H) and two identical light chains (L) 
L chains can be kappa or lambda; the H chains determine the class and subclass of 
Igs. In the five classes of immunolgobulins, IgG and IgM are the most frequently 
utilized antibodies in IHC.  
Polyclonal and monoclonal antibodies are available, based on their interactions with 
epitopes. The polyclonal antibodies are produced by different plasma cells and are 
immunochemically divergent. They also react with different epitopes on the antigen 
against which they are raised. Rabbit is the animal that is mostly used to produce 
polyclonal antibodies. The polyclonal antibodies can be harvested from animal blood 
either in the form of stabilized antisera or immunoglobulin fractions. Precipitation by 
salts and ion exchange chromatography are applied to remove the bulk of other serum 
protein. Next, affinity chromatography can be applied to isolate the antigen-specific 




Figure 7: Polyclonal antibodies. Adapted from Boenisch T (Ed):Handbook, 
immunochemical staining methods. 2001. 
 
Monoclonal antibodies are produced from an individual specific clone of plasma cells, 
which are identical and react with a particular epitope on the antigen against which 
they are raised. Mice are extensively used for production of monoclonal antibodies. 
When an immune response has been accomplished, the B lymphocytes of lymph 
nodes   and spleen are collected and fused to non-secreting mouse myeloma cells to 
produce hybridoma cells, and then the hybridoma is cultured and tested for specific 
antibody reactivity. The targeted epitope of monoclonal antibodies must be unique to 
the certain antigen, as the specificity of a monoclonal antibody can be lost if the 
antibody is against an epitope shared between different antigens [28]. 
In addition, dilution of antibody, incubation time and its reaction temperature are 
important factors when optimizing the IHC technique and any changes in one factor 




Figure 8: Monoclonal antibodies Adapted from Boenisch T (Ed):Handbook, 
immunochemical staining methods. 2001. 
 
1.3.2 Fixation 
The preservation of cells and tissues is an essential part of all histological and 
cytological techniques. Tissue blocks, sections and smear are immersed in fixative 
fluid. The fixative prevents autolysis by inactivating the lysosomal enzymes and 
inhibiting the bacterial growth. Moreover, fixatives stabilize the tissues and cells and 
protect them from damaged during sample processing and staining.  
Fixation techniques are different and tailored according to the various techniques 
applied in visualizing the structure of tissues or cells. The majority proportion of 
immunostaining samples is embedded in paraffin and many fixatives have been 
formulated with this. There are several fixatives including formaldehyde-based 
fixative (the most common fixative), acetic acid-zinc chloride, periodate-lysine-
paraformaldehyde (PLP), ethanol, and acetone  [28]. 
 
1.3.3 Antigen Retrieval 
The formalin-fixed paraffin-embedded (FFPE) tissues are the medium of choice in 
clinical and research studies, since it can generally preserve the morphology of cells 
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and tissues. However, fixation in formalin can mask many antigens of tissues and 
cause the loss of immunoreactivity. To improve the immunoreactivity of FFPE 
tissues, different antigen retrieval process emerged in history of IHC technique 
including the heating and enzymatic digestion methods  (proteolytic induced epitope 
retrieval). 
The principle of heating method depends on the time and temperature of heating in 
the FFPE tissues section. After deparaffinization and rehydration of tissue sections, 
the slides are immersed in retrieval solution (pH near 2, 6, 9, and 10). Following this 
step, the containers holding the slides are exposed to heat. This is the most critical 
step in antigen retrieval procedure. In addition, the duration and temperature of 
heating are important factors in antigen retrieval stage. Indeed, the majority of antigen 
retrieval methods used the temperature near boiling degree of water, also the optimal 
duration of heating varies from 10 to 60 minutes, for different fixation methods. The 
heating methods commonly used in IHC include the use of autoclaves, microwave 
oven, pressure cookers, steamers, and water baths. Consequently, each laboratory 
must identify the best antigen retrieval method for each antigen in specific tissues 
[28]. 
 
1.3.4 Enzyme Reaction 
Immunoenzymatic staining techniques use enzyme-substrate reactions to change 
colorless chromogens into colored ones. The expressed enzymatic activity is 
dependent upon factors, such as enzyme and substrate concentrations, salt 
concentrations of the buffer milieu, pH, temperature and light exposure. Selection of 
the specific enzyme for each IHC application depends on different criteria:  
1. The enzyme should be of high purity, but of reasonable cost. 
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2. Non-covalent binding and covalent binding to antibody and avidin 
respectively should not remove on attenuate the enzyme activity. 
3. The products of reaction should be stable and easy to detect.   
4. Active enzyme should be stable. 
 
Calf intestine alkaline phosphatase and horseradish peroxidise have most of the above 
mentioned criteria. Therefore, they are suitable enzymes for IHC application. 
Horseradishes peroxidise (HRP) enzyme is originated from the root of horseradish 
plant and its active site of haematin group generate its brown color when in solution. 
Like other enzymes, the activity of HRP can be stopped by excess substrate. There are 
several chromogens for the HRP enzyme including 3,3'-diaminobenzidine (DAB) 
with brown product, 3-amino-9-ethylcarbazole (AEC) with arose-red color end 
product, and 4-chloro-1-naphthol (CN) with blue product. 
calf intestine alkaline phosphatase (AP) removes and transfers the phosphate group of 
organic esters by demolishing the phosphor-diester (P-O) bond.  The key cationic 
activators for alkaline phosphatase are Mn++, Mg++, and Ca++.  In the AP staining 
technique, the AP hydrolyzes its substrate to phenolic compounds and phosphates, 
and subsequently reaction of phenolic compounds to colorless chromogens generates 
colored azo dyes. There are several chromogens for AP staining, such as fast red TR 
with red color product and fast blue BB with blue color product, and new fuchsin with 
red end product [28]. 
 
1.3.5 Staining Methods 
1.3.5.1 Direct staining technique 
The direct method is the oldest technique, in which an enzyme-labeled primary 
antibody interacts with the antigen in the tissue and then substrate-chromogen is 
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added to reveal the reaction sequence. Since this direct method utilizes only one 
antibody, it is relatively fast and has limited non-specific reactions. On the other hand, 
because staining involves just one labelled antibody, the signal of amplification is 
weak and it does not have adequate sensitivity for today’s demands. 
 
Figure 9: Direct method: enzyme labelled primary antibody reacts to tissue antigen. 
Adapted from Boenisch T (Ed):Handbook, immunochemical staining methods. 2001. 
 
1.3.5.2 Two-step indirect technique 
In this technique, a primary antibody binds to antigen, and then an enzyme-labeled 
secondary antibody is applied against the primary antibody which is now bound to 
antigen, followed by the last step, where in the substrate-chromogen solution is used 
to generate a colored product to enable detection these reactions. An important caveat 
is that the primary antibody is produced in mouse or rabbit, then the secondary 
antibody should also be raised against mouse or rabbit Igs, respectively. The indirect 






Figure 10: Two-step indirect method: Enzyme labeled secondary antibody reacts 
with primary antibody bound to tissue antigen Adapted from Boenisch T 
(Ed):Handbook, immunochemical staining methods. 2001. 
 
 
1.3.5.3 Avidin-biotin technology (ABC) 
This is the most popular immunostaining method and it is based on high affinity of 
avidin (streptomyces avidin and chicken egg) for biotin. Both of these two avidins 
have four sites for biotin, but because of the molecular orientation of the binding sites, 
fewer than four biotins will bind to avidin. In this method, primary antibody binds to 
antigen, and then biotinylated secondary antibody is applied against primary antibody, 
followed by adding the avidin-biotin-enzyme complex (ABC) or by the enzyme-
labeled streptavidin. [28] 
 
Figure 11: In the ABC technology: the streptoavidin-biotin-enzyme complex reacts 
with biotinylated secondary antibody Adapted from Boenisch T (Ed):Handbook, 
immunochemical staining methods. 2001. 
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1.3.5.4 Chain polymer-conjugated technology 
There are two systems, namely, the DAKO EPOS and DAKO Envision systems, that 
used the Chain polymer-conjugated technology. This method employs an enzyme-
labelled inert “spine” molecule of dextran and up to ten molecules of primary 
antibody can be attached to this spine molecule (polymer). 
In the enhanced polymer one step (EPOS) method, one step of the immunestaining 
product is eliminated to prior conjugation of primary antibody to enzyme-labeled 
dextran. However, in the Envision system, the immunostaining is carried out first with 
incubation of primary antibody followed by polymer addition. Since this system avoid 
using the (strep) avidin and biotin staining, the non-specific staining of endogenous 
biotin is reduced. 
The most important advantage of this technique is the reduced number of incubation 
steps for the staining protocol, which results in a more rapid procedure. On the other 
hand, increasing the incubation times of primary antibody and polymer can permit the 
dilution of antibodies several folds higher compared to what can be achieved in the 
standard ABC or LSAB protocols.  
 
Figure 12: In the two-step EnVision System: the primary antibody is followed by a 
spine molecule which contains an average of 10 molecules of secondary antibody and 
70 molecules of enzyme. Adapted from Boenisch T (Ed):Handbook, immunochemical 




1.3.5.5 Envision procedures for the simultaneous staining of several tissue 
markers 
The concurrent staining of two or more antigens has a lot of limitations which make 
their use impractical. However, the chain polymer technology of Envision system 
makes this application practical. In this system, the secondary antibodies against 
mouse and rabbits are conjugated to peroxidase- and alkaline phosphatase-labelled 
polymers. A leaching step prior to the use of extra primary antibodies removes 
previous primary and link antibodies and leaves just the deposit of chromogens from 

















Figure 13: Double staining by the Envision System: the first primary antibody (step 
3) is followed by the first spine molecule (step 4), use of a chromogen for the staining 
of the first antigen (step 5) is followed by a blocking reagent (step 7), application of 
the second primary antibody (step 8), the second spine molecule (step 9) and is 
concluded with the use of the second chromogen (step10). In this system a 
combination of rabbit polyclonal and/or mouse monoclonal primary antibodies, 
peroxidase and/or alkaline phosphatase, as well as chromogens such as DAB, 
Enhanced DAB, Fast Red, Fuchsin and BCIP/NBT can be used. (Peroxidase-block 
step and wash step were omitted in the figure. Adapted from Boenisch T 





1.3.6 Automation in immunehistochemistry 
In many histopathology laboratories, it is essential to develop an automation system, 
since manual efforts are not enough due to high demands for IHC as the most 
common diagnostic tool in pathology and hematology. There are several reasons that 
contribute to automate IHC, such as increasing output, improving reproducibility and 
quality, allowing better standardization and inter-laboratory comparison, and finally 
reducing the cost of labor and material.  
The commercially available types of automated IHC stainers vary in a number of 
aspects, including the slide capacity per run (20-500), the technology for processing 
of slides (capillary gap method, liquid cover slip method), and flexibility of reagents 
(open versus closed system).  
 
1.3.6.1 Bond-Max stainer 
The Bond-Max system automates advanced staining processes including 
immunohistochemistry (IHC) and in-situ hybridization (ISH). The Bond-Max system 
consists of a central host computer and has 30 slide capacity. Three trays of up to ten 
slides each can be processed simultaneously, using different protocols if required, 
with each tray started separately to provide continuous processing.  
Antigen retrieval procedures in Bond-Max include both enzyme and heating methods. 
There are two antigen retrieval solutions (ER1, ER2) for this heating system. Also, the 
temperature of ER solutions in this part would be around 100 C and the incubation 







1.3.6.2 Ventana BenchMark XT 
This is a flexible automation stainer for IHC, ISH, FITC, and FISH methods.  
Optimization of protocols with different options such as extended incubation times 
and different temperatures are possible with this machine. Besides, there is a 
possibility to choose different primary antibodies from any vendor. 
This system has two antigen unmasking techniques, which are heating (CC1) and 
enzyme (CC2) methods. CC1 is a Tris-based buffer with a slightly basic pH, which, at 
elevated temperatures, is capable of hydrolyzing the covalent bonds formed by 
formalin in tissue. Removing these bonds allows renaturation of protein molecules 
and increases antibody accessibility. Often these changes result in significant gains in 
antibody binding and improved signal-to-noise ratios. The automated slide stainer 
automatically heats the slide to the appropriate temperature and time as selected by 
the user. There are three CC1 condition: CC1 mild (30 min), CC1 standard (60 min), 





Ventana Benchmark XT stainer 
 
1.4 Background, Significance and Experimental Design 
The main risk of genomic damage in mitotic cells is mutation. In addition, the host 
genome is always affected by many factors including the environment, products of 
oxidation metabolism, errors in DNA replication, etc. In the event of genetic damages 
by various extrinsic and/or intrinsic factors, the affected cells may attempt to repair 
these damages or may decide to sacrifice themselves. However, a few cells may 
accumulate the genetic instability and develop cancer. 
Tumorgenesis is an evolutionary process in multicellular organisms that selects for 
epigenetic and genetic changes that are detrimental to the preservation of their 
survival. These changes prevent the anti-proliferative and cell death-inducing 
mechanisms that result in restricting the clonal growth of transformed somatic cells. 
The majority of tumors acquire genetic instability, but it is not clear when and how 
these early genetic instabilities persist, initiate, and promote cancer development. In 
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multicellular organisms, apoptosis and senescence are two cellular mechanisms that 
impede cell proliferation at the oncogenic transformation time. 
  In recent studies, the DNA Damage Response (DDR) and oncogene-induced 
senescence (OIS) have been proposed as two important in vivo barriers to tumor 
expansion [30‐35]. These studies demonstrated the existence of DDR and OIS markers 
in a range of premalignant tumors, including those of the lung, skin, colon, prostate, 
and bladder, but more importantly, they also showed the absence of these markers 
upon transformation to malignant tumors.  
An intricate balance between cell proliferation, cellular senescence and cell death 
construct a well-orchestrated harmony in cells. The widespread researches on tumor 
suppressor genes, oncogenes, cell cycle, and apoptosis regulatory genes, many of 
which are still ongoing, have shown how the DNA damage-sensing and -signalling 
pathways are associated with the DNA-damage response (DDR) network, cell-cycle 
arrest, cellular senescence and apoptosis.  
Under conditions of stress, and even during normal cell cycle, checkpoint proteins 
play an important role in genome maintenance through the activation of DNA damage 
response (DDR). The DDR network is complex and involves a large number of 
proteins that sense the damage, transduce signals into cells, and complete cellular 
responses. DNA damages such as double-strand DNA breaks (DBS) are detected by 
different sensor proteins such as NBS1/Mre11/Rad50 in the nucleus of cells, which 
transmit the DNA damage signals via ATR (ATM and Rad3-related) or ATM  (ataxia-
telangiectasia, mutated) proteins to CHK1 (checkpoint kinase1) and CHK2 
(checkpoint kinase2) proteins. Activation of these checkpoint kinases meditates 
activation of their downstream targets, including MDM2, p53, CDC25A, Rb, and 
38 
 
SMC1. Finally, the ATM and ATR activation results in G1 or G2 cell cycle arrest and 
triggers apoptosis or senescence (Figure 14) [36,37]. 
Activation of DDR checkpoints such as p-CHK2 (phospho-CHK2) and ATM were 
investigated in the early stages to advanced stages of bladder cancer by applying IHC, 
whereupon the strong positive staining was found in superficial lesions (Ta) and the 
early invasive stage (T1) of bladder carcinoma [30‐35]. However, the more advanced 
stages (T2-T4) showed moderately lower staining in IHC. In addition, normal bladder 
tissues were completely negative for p-CHK2 staining. Analogous to its association 
with effects on bladder carcinoma, DDR activation was detectable in the majority of 
244 invasive carcinomas of the colon, breast or lung. In contrast, 87 samples from 
normal, proliferative tissues, and also 26 inflammatory tissues showed negative DDR 
activation.  Furthermore, the majority of pre-invasive carcinomas including lung 
hyperplasia, in situ lesions of breast cancer, and colorectal adenomas were strongly 
positive for DDR checkpoints. These results demonstrated that activation of DDR 
checkpoints occurs in premalignant tissues prior to progression to more advanced 
stages of cancers, presumably to prevent cancer formation in these tissues.  Indeed, 
IHC staining of DDR checkpoints were strongly positive in premalignant tissues, but 







Figure 14: The DNA-damage response. Adapted from Campisi J, d'Adda di 
Fagagna F: Cellular senescence: when bad things happen to good cells. Nat Rev Mol 
Cell Biol 2007, 8(9):729-740  
 
Cellular senescence was first described by Hayflick and colleagues in cultured cells. 
They showed that normal fibroblast cells had a limited capacity to proliferate in 
culture. Now, the senescence concept is generally applied to the irreversible growth 
arrest of cells due to various stress conditions, including telomere dysfunction, DNA 
damage, oncogenic activation, oxidative damage, and several chemotherapeutic drugs.  
There are several forms of senescence. The first is replicative senescence, the form 
stimulated by eroded telomeres, which relies on DDR pathways and activation of 
ATM and ChK2 proteins.  A second type of senescence, which is induced by 
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cytotoxic agents, causes DNA double strand breaks (DBS) and also depends on ATM 
and CHK2 activations. Oncogene-induced senescence (OIS) is the third form of 
senescence that has been linked to activation of p16 and ARF rather than DNA 
damage response (DDR) or DNA DSB checkpoint pathway. Investigation of signaling 
pathways that are important for OIS has identified two main pathways, namely, the 
p16-Rb pathway and the ARF-p53 pathway (Figure 15). These two pathways are 
crucial for tumor suppression and are frequently altered, primarily due to mutated 
intermediates, in tumors. In fact, activation of OIS during tumorigenesis inhibits 
cancer formation. Thus, senescent cells are abundant in preneoplastic lesions 
compared to neoplastic tissues [32,38].  
Moreover, recent studies demonstrated that OIS is connected to the presence of DNA 
damage and also the full activation of DDR pathways. [34] Therefore, efficient DDR 
activity is essential to initiate and drive OIS, and its loss allows damaged cells to 
proliferate. Indeed, the enforcement of DDR is both causative and necessary in the 
formation and maintenance of OIS. Furthermore, senescence is preceded by a 
“proliferation explosion”, suggesting that OIS and DDR are interlinked with and 







Figure15: A) p16INK4a-pRb senescence pathway. B)  ARF-p53 senescence 
pathway. Adapted from Campo-Trapero J, Cano-Sánchez J, Palacios-Sánchez B, 
Llamas-Martínez S, Lo Muzio L, Bascones-Martínez A: Cellular senescence in oral 
cancer and precancer and treatment implications: a review. Acta Oncol 2008, 









Figure 16: Oncogene-induced DNA damage model for cancer development and 
progression. Genomic instability and tumor suppression are direct outcomes of 
oncogene-induced DNA replication stress and are both present from the beginning of 
cancer development, before the transition from precancerous lesion to cancer. 
Adapted from Halazonetis TD, Gorgoulis VG, Bartek J: An oncogene-induced DNA 
damage model for cancer development. Science 2008, 319(5868):1352-1355 with 
modification.  
 
The specific association of DDR and OIS with premalignant lesions might provide a 
unique opportunity to use the apoptotic and senescence markers as indicators of early 
stages of tumorigenesis events. It stands to reason that the markers that have been 
identified in previous studies of OIS and DDR could help in cancer staging and 
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treatment. In addition, chemotherapeutic drugs may induce senescence and DDR in 
tumor cells and thus monitoring of these markers will help to check the efficacy of 
therapy.  Finally, recognition of additional markers of OIS and DDR and the 
evaluation of their values in diagnosis and prognosis offer valuable future prospects 
for fighting cancer. 
In MGUS, oncogene activation by translocations involving the IgH (immunoglobulin 
heavy chains) locus, genomic instability with aneuploidy, and cell cycle deregulation 
by aberrant and universal D-type cyclins, are already well studied. Yet there is a long 
latency between MGUS and its progression to symptomatic myeloma. In addition, a 
few other transitional events have been implicated as contributory to transformation 
from MGUS to MM. One potential transition event is ras mutation, but it was found 
in just about 20% of patients at diagnosis and enriched in certain genetic subtypes 
such as: t(11;14) [40]. Also, a difference in hypermethylation of the promoter region 
of genes such as E-Cadherin and p16 between MGUS and MM was observed, but the 
functional effects of these changes, if any, are unknown [41]. In the case of p16, 
promoter hypermethylation did not appear to affect mRNA expression as the gene 
has, generally, a low expression in plasma cells [42]. Moreover, a new study 
investigated the methylation status of 6 tumor suppressor genes, including p14, p15, 
p16, hMLH1, MGMT, and DAPK and their association with loss of gene function 
[43]. Among these 6 genes, a loss of hMLH1 expression was observed in half of the 
MM cases compared to none of the MGUS or plasmacytoma cases. Thus, the loss of 
hMLH1 can plausibly play a role in the malignant transformation of plasma cells [43]. 
Another transition event is a breakdown in the immune surveillance by a reversible 
defect in NK T cells, which may contribute to transition from MGUS to MM [44]. A 
global genome study on MGUS and MM in Chinese patients has revealed that a 
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higher number of chromosomal imbalances and specific genetic alterations are 
involved in MGUS to MM transition (-6q,+ 3p, and+1p) and MM progression (+2p 
and +9q) [45]. In addition, Herve et al. showed that monosomy 13 is correlated with 
the transformation of MGUS to overt MM [46]. In contrast, Kaufmann et al. stated 
that IgH translocations and/or Del (13q) are early genetic events in monoclonal 
gammopathies and are not related to transformation events [47]. The summary of all 
studies which are directly or indirectly involved in transformation of MGUS to MM is 
shown in Table 5.  
As was mentioned earlier, there is a long latency between MGUS and its progression 
to symptomatic myeloma. This suggests the existence of one or more tumorigenic 
barriers in MGUS prior to malignant transformation. Based on recent studies 
regarding activation of DDR and OIS in some premalignant tumors, we hypothesized 
that the absence of DDR checkpoint and senescence might be prime candidates in 
transformation of MGUS to MM. In support of our hypothesis, the presence of these 
tumorigenic barriers have been displayed in a mouse model of lymphoma, but they 
have not been demonstrated as yet in human hematological malignancies such as 
MGUS and MM [48].  
In this study, we planned to collate and investigate the evidence and functional 
relevance of DDR and senescence in relation to cellular phenotype by using tumor 
samples from MM and MGUS patients. We would also look at the proliferation, pro-
apoptotic and anti-apoptotic markers to evaluate the association of these markers with 






Table 5: Literature review for transformation of MGUS to MM 
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2. Methods & Materials 
2.1 MM Samples 
Based on availability of clinical data and bone marrow biopsy (paraffin-embedded 
block), 92 myeloma patients were selected from NUH paraffin-embedded tissue 
archival.  The 600 slides (a combination of H&E and different markers of IHC 
staining) from some of these patients were reviewed by a pathologist and a 
hematologist.  In this review, patients with clinical diagnosis of MM and more than 15 
percent plasma cells in bone marrow biopsy were selected as our MM samples. 
According to the first review of 92 MM patients, 10 patients were included, 14 
patients excluded, and 78 patients were candidates for CD138 (marker of plasma cell) 
IHC and H& E staining.  
In the next step, roughly 250 sections from 120 BMBs were cut and stained for H& E 
and CD138 (IHC) staining. In this second review, 17 patients were excluded and 47 
included to our MM sample size. On the other hand, four cases were selected for 
repeating the CD138 and MUM1 (another marker of plasma cell). After repeating the 
CD138 and MUM1 IHC staining, 3 patients were excluded and 1 patient included to 
our cohort study of MM patients. In total, we had 58 MM patients with more than 
15% plasma cells infiltration in the bone marrow biopsy of each patient. 
Approximately 25 to 30 sections of 3 to 4 micrometer thickness were cut for each 
patient and all 1500 sections stored in the minus 20 degree freezer.  
Seventeen MGUS BMB samples were collected from NUH paraffin-embedded tissue 




2.2 IHC single staining 
Immunohistochemistry technique was selectively applied using a variety of different 
markers of senescence, apoptosis, and proliferation to the slides prepared as described 
above. Single staining IHC was optimized for CD138, MUM1, p53, Ki67, MDM2, p-
CHK2, p-p53, CD20, and Bcl-2 markers and then all markers except MUM1 were 
tested for each MM sample individually. Finally, scoring of each marker was carried 
out by comparing the location of plasma cells in CD138 slide in every patient. 
 
2.3 IHC double staining 
Single staining technique was replaced by double staining method, since single IHC 
staining was not as accurate method to identify the plasma cells in different bone 
marrow cells and also was not able to evaluate the expression level of diverse markers 
in plasma cells precisely. In double staining IHC, one plasma marker (CD138 
membrane staining or MUM1 nuclear staining) was combined with each of our 
interest markers such as p53, Ki67, Bcl-2, CD20. Indeed, by double staining method, 
all plasma cells were labeled by CD138 or MUM1, and then expression of second 
markers was evaluated in labeled cells (plasma cell). 
 The Bond-Max stainer was used for optimizing diverse combinations such as 
CD138/Ki67, CD138/p53, CD138/Bax, CD138/MDM2, MUM1/CD20, and 
MUM1/Bcl-2. When the optimizations in positive control tissues were completed, 
each combination of double staining was applied to all 58 MM samples (around 350 
tests). 
Scoring the double staining slides and comparing the result of double staining with 
those for single staining revealed an important problem in our Bond-Max staining 
system. Based on our effort to find out the problem, it was released that the AP red 
49 
 
detection Kit only worked randomly in each running. Another new AP red detection 
kit was tested and also had the same problem as the old kit. After a few months of 
evaluation work, it was clear that the reagent of Bond-Max stainer, AP red kit, was 
not suitable for double staining protocols in bone marrow.  
The second double staining optimizations were carried out using the Ventana 
BenchMark XT stainer. Several combinations, including CD138/p53, CD138/Ki67, 
CD138/Bax, CD138/Bcl-1, CD138/Cleaved caspase 3, and CD138/p16 were 
optimized in this new machine. Finally, optimized protocols were applied to stain 
MM and MGUS sections and approximately 500 double staining tests were 
completed. 
 
2.4 Single IHC Scoring 
In each patient, five random fields of each marker were compared with the same 
fields of CD138 slide, which was viewed by 40X microscope objective. In the 
comparison of CD138 slide with any other markers, the location of plasma cells 
(positive CD138 cells) in CD138 slides were identified and then were correlated to 
the positive cells in slides of other markers. To get a ratio for expression level of each 
marker, the total numbers of positive plasma cells for each marker in all five fields 
were divided by the total numbers of CD138 cells and then this ratio were stated as 
percentage. 
 
2.5 Double IHC Scoring 
Scoring the double staining IHC slides is both accurate and easy to perform. In each 
slide, CD138 or MUM1 markers (plasma cell makers) were combined with another 
marker to evaluate expression level of the new marker in plasma cells (CD138 or 
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MUM1 positive cells). Five random fields were selected for any combination of 
double-staining slides. In the next step, the total numbers of double stained cells in 
five fields were divided by the total number of CD138 or MUM1 positive cells, and 
then this ratio were expressed as percentage for any markers.   
 
2.6 Cut off determination for each marker 
The cutoff point was different for each marker. A case was considered positive for 
Cyclin D1 or p53 if there was positive staining in ≥5% of plasma cells. In addition, 
positive staining in ≥ 1% of plasma cells was considered as cutoff point for Ki67, p16, 
and CC3. However, a case with Bax or Bcl-2 expression ≥50% of plasma cells was 
supposed as Bax and/or Bcl-2 overexpression case.   
 
2.7 Dewaxing and hydration of tissue 
Paraffin embedded sections were put on xylene solution 1 and 2 for five minutes each, 
and  were rehydrated in graded concentration of ethanol (100%, 95%, 95% to 70%) 
and then were rinsed with distilled water. 
 
2.8 Hematoxiline and Eosin Staining (H&E) 
After deparaffinization and rehydration, sections were put into haematoxylin solution for 
1 minute to stain nuclei, and then rinsed in running tap water. In addition, sections were 
dip in 0.3% acid alcohol one time and rinsed in running tap water. In the next step, 
sections were stained by Eosin for 2 minutes, rinsed by water, dehydrated by using 70%, 
95%, 100%, 100% ethanol solutions and then cleared by xylene and mounted with DPX. 
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2.9 IHC staining 
2.9.1 IHC protocol for CD138 (Single staining) 
Paraffin sections were dewaxed in xylene and hydrated through the graded 
concentration of ethanol. Section was pressure cooked for 3 minutes at full pressure. 
Endogenous peroxidase activity in tissue was blocked with 3% hydrogen peroxide for 
10 min. Incubate with CD138 diluted 1:100 and stain for 1 hour at room temperature 
(RT). CD138 was rinsed off with TBS and incubated with Detection reagent (DAKO 
ChemMate, Envision HRP kit).  Freshly prepare DAB was applied for 6 min after 
rinsing off the reagent with TBS.  Excess DAB was rinse off before counter-stain with 
hematoxylin.  Sections were then dehydrated in graded concentration of ethanol, 
cleared in xylene and mounted with DPX. 
 
2.9.2 IHC protocol for MUM 1 (Single staining) 
Paraffin sections were dewaxed in xylene and hydrated through the graded 
concentration of ethanol. Sections were cooked with DAKO TRS buffer (pH 9.0) for 
20 minutes in Microwave and washed in TBS.  Endogenous peroxidase activity in 
tissue was blocked with 3% hydrogen peroxide for 10 min. Sections were incubated 
with MUM 1 diluted 1:50 and stains for 1 hour at RT. MUM1 was rinsed off with 
TBS and incubated with Envision HRP detection kit. Freshly prepare DAB was 
applied for 6 min after rinsing off the reagent with TBS.  Excess DAB was rinsed off 
before counter-stain with hematoxylin.  Sections were then dehydrated in graded 




2.9.3 IHC protocol for p53 (Single staining) 
Paraffin sections were dewaxed in xylene and hydrated through the graded 
concentration of ethanol. Sections were cooked with DAKO TRS buffer (pH 6.0) for 
20 minutes in Microwave and washed in TBS.  Endogenous peroxidase activity in 
tissue was blocked with 3% hydrogen peroxide for 10 min. Sections were incubated 
with p53 diluted 1:100 and stained for 1 hour at RT. p53 was rinsed off with TBS and 
incubated with Envision HRP detection kit. Freshly prepare DAB was applied for 6 
min after rinsing off the reagent with TBS.  Excess DAB was rinse off before counter-
stain with hematoxylin.  Sections were then dehydrated in graded concentration of 
ethanol, cleared in xylene and mounted with DPX. 
 
2.9.4 IHC protocol for Ki 67 (Single staining) 
Paraffin sections were dewaxed in xylene and hydrated through the graded 
concentration of ethanol. Sections were cooked with DAKO TRS buffer (pH 6.0) for 
20 minutes in Microwave and washed in TBS.  Endogenous peroxidase activity in 
tissue was blocked with 3% hydrogen peroxide for 10 min. Sections were incubated 
with Ki-67 diluted 1:200 and stained for 1 hour at RT.  Ki67 was rinsed off with TBS 
and incubated with Envision HRP detection kit. Freshly prepare DAB was applied for 
6 min after rinsing off the reagent with TBS.  Excess DAB was rinsed off before 
counter-stain with hematoxylin.  Sections were then dehydrated in graded 
concentration of ethanol, cleared in xylene and mounted with DPX. 
 
2.9.5 IHC protocol for Bcl-2 (Single staining) 
Paraffin sections were dewaxed in xylene and hydrated through the graded 
concentration of ethanol. Sections were cooked with DAKO TRS buffer (pH 9.0) for 
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20 minutes in Microwave and washed in TBS. Endogenous peroxidase activity in 
tissue was blocked with 3% hydrogen peroxide for 10 min. Sections were incubated 
with Bcl2 diluted 1:100 and stained for 1 hour at RT. Bcl2 was rinsed off  with TBS 
and incubated with Envision HRP detection kit. Freshly prepare DAB was applied for 
6 min after rinsing off the reagent with TBS.  Excess DAB was rinsed off before 
counter-stain with hematoxylin.  Sections were then dehydrated in graded 
concentration of ethanol, cleared in xylene and mounted with DPX.. 
 
2.9.6 IHC protocol for CD 20 (Single staining) 
Paraffin sections were dewaxed in xylene and hydrated through the graded 
concentration of ethanol. Sections were cooked with DAKO TRS buffer (pH 9.0) for 
20 minutes in Microwave and washed in TBS. Endogenous peroxidase activity in 
tissue was blocked with 3% hydrogen peroxide for 10 min. Sections were incubated 
with CD 20 diluted 1:100 and stained for 1 hour at RT. CD 20 was rinsed off with 
TBS and incubated with Envision HRP detection kit. Freshly prepare DAB was 
applied for 6 min after rinsing off the reagent with TBS.  Excess DAB was rinse off 
before counter-stain with hematoxylin.  Sections were then dehydrated in graded 
concentration of ethanol, cleared in xylene and mounted with DPX. 
 
2.9.7 IHC protocol for p-p53 (Single staining) 
Paraffin sections were dewaxed in xylene and hydrated through the graded 
concentration of ethanol. Sections were cooked in 118 degree with DAKO TRS buffer 
(pH 6.0) for 20 minutes by pressure cooker and washed in TBS.  Endogenous 
peroxidase activity in tissue was blocked with 3% hydrogen peroxide for 10 min. 
Incubate section with p-p53 diluted 1:100 and stain for 24 hour at four degree. p-p53 
54 
 
was rinsed off the with TBS and incubated with Envision HRP detection kit. Freshly 
prepare DAB was applied for 6 min after rinsing off the reagent with TBS.  Excess 
DAB was rinse off before counter-stain with hematoxylin.  Sections were then 
dehydrated in graded concentration of ethanol, cleared in xylene and mounted with 
DPX. 
 
2.9.8 IHC protocol for p-CHK2 (Single staining) 
Paraffin sections were dewaxed in xylene and hydrated through the graded 
concentration of ethanol. Sections were cooked with DAKO TRS buffer (pH 6.0) for 
20 minutes in Microwave and washed in TBS. Endogenous peroxidase activity in 
tissue was blocked with 3% hydrogen peroxide for 10 min. Incubate section with p-
CHK2 diluted 1:100 and stain for 1 hour RT. p-CHK2 was rinsed off with TBS and 
incubated with Envision HRP detection kit. Freshly prepare DAB was applied for 6 
min after rinsing off the reagent with TBS.  Excess DAB was rinse off before counter-
stain with hematoxylin.  Sections were then dehydrated in graded concentration of 
ethanol, cleared in xylene and mounted with DPX. 
 
2.9.9 IHC protocol for MDM2 (Single staining) 
Paraffin sections were dewaxed in xylene and hydrated through the graded 
concentration of ethanol. Sections were cooked in 118 degree with DAKO TRS buffer 
(pH 6.0) for 30 minutes by pressure cooker and washed in TBS. Endogenous 
peroxidase activity in tissue was blocked with 3% hydrogen peroxide for 10 min. 
Sections were incubated with MDM2 diluted 1:100 and stained for 1 hour at RT. 
MDM2 was rinsed off with TBS and incubated with Envision HRP detection kit. 
Freshly prepare DAB was applied for 6 min after rinsing off the reagent with TBS.  
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Excess DAB was rinse off before counter-stain with hematoxylin.  Sections were then 




















with DAB detection 
kit 
Second marker 
staining protocol  
with AP red 
detection kit 
CD138/p53 CC1-standard  
(60 minutes) 
CD138 incubation 40 
min with 37 C, 
dilution 1:100 
p53 incubation 40 
min with 37 C, 
dilution 1:100  
CD138/Ki67 CC1-standard  
(60 minutes) 
CD138 incubation 40 
min with 37 C, 
dilution 1:100 
Ki67 incubation 40 
min with 37 C, 
dilution 1:100 
CD138/Bax CC1-extended  
(90 minutes) 
CD138 incubation 40 
min with 37 C, 
dilution 1:100 
Bax incubation 40 
min with 37 C, 
dilution 1:50 
CD138/Bcl-1 CC1-extended  
(90 minutes) 
CD138 incubation 32 
min with 37 C, 
dilution 1:100 
Bcl-1 incubation 32 
min with 37 C, 
dilution 1:20 
CD138/p16 CC1-standard  
(60 minutes) 
CD138 incubation 32 
min with 37 C, 
dilution 1:100 
p16  incubation 32 
min with 37 C, 
dilution 1:50 
CD20/MUM1 CC1-standard  
(60 minutes) 
CD138 incubation 40 
min with 42 C, 
dilution 1:100 
MUM1 incubation 40 
min with 42 C, 
dilution 1:100 
CD138/CC3 CC1-mild 
 (30 minutes) 
CD138 incubation 40 
min with 42 C, 
dilution 1:100 
CC3  incubation 60 









First marker staining 
protocol with  bond 
polymer refine detection 
kit 
Second marker staining 
protocol with bond 
polymer AP red 
detection kit 
CD138/p53 CD138  incubation 30 min 
CD138 dilution 1:100 
ER2 (Antigen retrieval) 20 
min 
Detection kit (Bond 
polymer refine kit) 70 min 
 
p53 incubation 30 min 
p53 dilution 1:100 
ER1 (antigen retrieval)  20 
min 
Detection kit (Bond 
polymer AP red) 75 min 
CD138/Ki67 CD138  incubation 30 min 
CD138 dilution 1:100 
ER2 (Antigen retrieval) 20 
min 
Detection kit (Bond 
polymer refine kit) 70 min 
 
Ki67 incubation 30 min 
Ki67 dilution 1:200 
ER1 (antigen retrieval)  20 
min 
Detection kit (Bond 
polymer AP red) 75 min 
CD138/Bax CD138  incubation 30 min 
CD138 dilution 1:100 
ER2 (Antigen retrieval) 20 
min 
Detection kit (Bond 
polymer refine kit) 70 min 
 
Bax incubation 30 min 
Bax dilution 1:50 
ER2 (antigen retrieval)  20 
min 
Detection kit (Bond 
polymer AP red) 75 min 
CD138/MDM2 CD138  incubation 30 min 
CD138 dilution 1:100 
ER2 (Antigen retrieval) 20 
min 
Detection kit (Bond 
polymer refine kit) 70 min 
 
MDM2 incubation 30 min 
MDM2 dilution 1:50 
ER1 (antigen retrieval) 20 
min 
Detection kit (Bond 
polymer AP red) 75 min 
CD20/MUM1 CD20  incubation 30 min 
CD20 dilution 1:1500 
ER2 (Antigen retrieval) 20 
min 
Detection kit (Bond 
polymer refine kit) 70 min 
 
MUM1 incubation 30 min 
MUM1 dilution 1:100 
ER1 (antigen retrieval) 20 
min 
Detection kit (Bond 
polymer AP red) 75 min 
 
Bcl-2/ MUM1 Bcl-2  incubation 30 min 
Bcl-2 dilution 1:100 
ER2 (Antigen retrieval) 20 
min 
Detection kit (Bond 
polymer refine kit) 70 min 
 
MUM1 incubation 30 min 
MUM1 dilution 1:100 
ER1 (antigen retrieval) 20 
min 
Detection kit (Bond 





*ER1: antigen retrieval solution 1, *ER2: antigen retrieval solution 2 
 
2.10 Double IHC staining in automated stainer 
The two systems of automated stainer, Bond-Max and Ventana Bnchmark, have 
different programs for running the double staining IHC and also their antigen retrieval 
are particular for each stainer. Antigen retrieval procedures in Bond-Max include both 
enzyme and heating methods with two antigen retrieval solutions (ER1, ER2) for this 
heating system. In addition, the Ventana BenchMark applies two antigen unmasking 
techniques, including heating (CC1) and Enzyme (CC2). The CC1 that were used in 
this study is a Tris-based buffer with a slightly basic pH and has three conditions 
based on temperature and time of heating: CC1 mild (30 min), CC1 standard (60 
min), CC1 Extended (90 min). All optimized double staining IHC protocols were 
summarized in Table 6, and 7. 
2.11 Statistical analysis 
Statistical data was computed utilizing SPSS version 17.0. Fisher exact test for two 
categorical variables was applied to identify the relationship between diagnosed group 
(MM and MGUS) and expression of each marker. In addition, Mann-Whitney U test 
applied to compare the Bcl-2/Bax ratio between MM and MGUS samples. Statistical 
significance was set at p<0.05.  
The survival analysis of myeloma patients was done using Graphpad Prism software. 
The survival curves were constructed according to the Kaplan-Meier method and then 






2.12 Reagents for single staining IHC 
Dako wash buffer (S3006) 
Dako antibody diluents (S0809) 
Dako proxidase blocking reagent (S2001) 
Dako target retrieval solution (S1699) 
Dako target retrieval solution high pH (S3307) 
Dako Real TM (HRP Rabbit/ Mouse) (K5007) 
Dako Real TM (Substrate buffer) 
Dako Real TM (DAB + chromogen X50) 
 
2.13 Leica Bond-Max reagents 
Bond epitope retrieval solution 1 (1L AR9961) 
Bond epitope retrieval solution 2 (1L AR9640) 
Bond wash solution 10X (1L AR9590) 
Bond primary antibody diluents (1L AR9362) 
Bond dewax solution (4×1L AR9222) 
Bond DAB enhancer (30mL AR9432) 
Bond polymer AP red detection kit (DS9305) 
Bond polymer refines detection kit (DS9800) 
 
2.14Ventana BenchMark XT reagents 
Ultraview Red Detection Kit (760-501) 
Bluing Reagent (760-2037) 
Haematoxylin II (790-2208) 




Ultraview DAB Detection Kit (760-500) 
Reaction buffer (950-30PC) 
LCS (650-010) 
EZ PREP solution (950-102) 
 
Table 8: Characteristic of utilized antibodies 
 
Antibody Name Type Company Catalogue 
Number 
Bcl-1 (SP4) Rabbit 
Monoclonal 
















Cleaved Caspase3 Rabbit 
polyclonal 































Table 9: Positive control tissues for each antibody 
 





p-p53 Breast carcinoma 
MDM2 Tonsil 
CD20 Tonsil 
Bax Hodgkin’s lymphoma 
P16 Tonsil, cervix 
Cleaved caspase 3 Tonsil 
p-CHK2 Breast carcinoma 

















3.1 Evaluation of p53 expression 
3.1.1Staining pattern 
The staining pattern of p53 expression is nuclear that is shown as red color (Figure 
18). However, the CD138 (plasma cell marker) stains the membrane of plasma cells 
with brown color. Therefore, the positive plasma cells for p53 expression have a 
combination of red color in the nucleus and brown color on the membrane (Figure18). 
In this study, sample with more than 1 % positive p53 plasma cells was considered as 
positive case for p53 expression. 
 
3.1.2 p53 expression in MGUS and MM 
The results of p53 expression for MGUS and MM samples did not show any 
significant difference (p-value 0.109). All p53 positive cases (12%, 9 from 75 cases) 
had MM diagnosis and there were not positive p53 cases in MGUS patients (Table 
10).  
However, the survival analysis of the MM p53 positive patients indicated a significant 
association (log-rank p-value= 0.0003) between p53 expression and poor prognosis in 
MM patients. The median overall survival of p53 positive cases was 4.4 months while 
the median survival of p53 negative cases was 84 months (Figure 19). In addition, the 











Figure18: A) Negative p53 expression in CD138/p53 double staining of MM case.  
















Figure 19: Overall survival of patients with positive p53 expression was significantly 
less than that of patients with negative p53% expression (log-rank p-value=0.0003) 
 
3.2 Evaluation of Bax and Bcl-2 expression 
3.2.1 Staining pattern of Bax 
Bax expression has cytoplasmic staining that is shown as red color in Figure 20. 
Erythroid and myeloid precursors in bone marrow served as internal positive controls 
for Bax expression, whilst the CD138 (plasma cell marker) stains the membrane of 
plasma cells with brown color. Therefore, plasma cells that have positive Bax 
expression, have a combination of red color in the cytoplasm and brown color on the 
cell membrane (Figure 20). In this study, plasma cell samples with more than 49 % 





Figure 20: A) An MM case showing Bax expression >90% at 20X magnification. B) 









Figure 20: C) Low expression of Bax in MGUS case at 20X magnification. D) The 
same case of MGUS at 40X magnification. Bax has cytoplasmic staining in some 







3.2.2 Staining pattern of Bcl-2 
Bcl-2 expression has cytoplasmic staining which is shown as a brown color in Figure 
21. The internal positive Bcl-2 control in bone marrow is the lymphocyte. The 
morphology of plasma cells (small sized cells with prominent cytoplasm, and 
eccentric nucleus with dense chromatin) and also location of plasma cells in CD138 
slides helped to differentiate plasma cells from lymphocyte in Bcl-2 
immunohistochemistry staining. In this study, samples with more than 49 % Bcl-2 
positive plasma cells were considered as positive cases for overexpression of Bcl-2. 
 Bcl-2 is the only single staining marker in this study, because all optimization 




Figure 21: A) An MM case showing Cytoplasmic expression of Bcl-2 ≥ 90% in 








Figure 21: B) the same case of MM with 40X magnification C) low expression of 







3.2.3 Bax and Bcl-2 expression in MGUS and MM patients 
The results of Fisher exact test for Bax and Bcl-2 expression showed significant 
difference between MGUS and MM patients (p-value 0.001 and p-value< 0.001 
respectively). As it is shown in Table 10, a large proportion of MM patients (65.5% 
and 76.4%) had over expression of Bax and Bcl-2 respetively, while a small fraction 
of MGUS patients showed overexpression of Bax (17.6%) and Bcl-2 (11.8%). 
However, the Mann-Withney U test for Bcl-2/Bax ratio did not reveal any significant 
association between MGUS and MM groups (p=0.209).  
Interestingly, the survival analysis of MM patients indicated a significant association 
(log-rank p-value= 0.04) between Bcl-2 overexpression and poor prognosis in MM 
patients. The median overall survival of 51.5 months versus 84 months was obtained 
for cases with high Bcl-2 overexpression compared to those with low Bcl-2 
expression (Figure 22.A). However, there was no association between Bax expression 
or Bcl-2/Bax ratio and MM prognosis (log-rank p-value= 0.46 and p=0.93) (Figure 
22.B and Table 10) 
 
Table 10: Result of Bax and Bcl-2 over expression in MGUS and MM samples. 




42/55 (76.4%) 2/17 (11.8%) <0.001 0.04 
Bax 
overexpression 
38/58 (65.5%) 3/17 (17.6%) 0.001 0.46 
Bcl-2/Bax 
  




























Figure 22: A) Overall survival of MM patients with high expression of Bcl-2 was 
significantly less than patients with low expression of Bcl-2. B) There was no 





Figure 23: Overexpression of Bax and Bcl-2 has been shown in MM patients 
compared to MGUS patients. But, the Bcl-2/Bax ratio did not show any difference 
between these two group of patients. 
 
3.3 Evaluation of Ki67 and Cycline D1 expression 
3.3.1 Staining pattern of Ki67 
The nuclear staining pattern of Ki67 expression detected in proliferative cells is 
shown in Figure 24 as red color. Whilst, the CD138 (plasma cell marker) stains the 
membrane of plasma cells with brown color in double-staining IHC. Thus, the 
proliferative plasma cells had a combination of red color in nucleus (Ki67) and brown 
color on the plasma cell membrane (CD138) (Figure 23). In this study, any sample 







Figure 24: A) MM case with positive ki67 expression in plasma cells which is 
pointed (40X magnification) B) MM case with few positive ki67/CD138 double 









Figure 24: C) MM case with negative Ki67/CD138 staining D) MGUS case with 






3.3.2 Staining pattern of Cyclin D1 
Staining pattern of Cyclin D1 expression shown as red color in Figure 25 is mainly 
nuclear and less cytoplasic. While, the CD138 (plasma cell marker) stains the 
membrane of plasma cells with brown color in double staining IHC. Therefore, the 
positive Cyclin D1 plasma cells had a combination of red color in nucleus and also 
cytoplasm (Cyclin D1) and brown color in membrane (CD138) (Figure 25). In this 











Figure 25: B) MM patient with negative expression of Cyclin D1 in plasma cells C) 










3.3.3 Cyclin D1 and Ki7 expression in MM and MGUS 
Table 11 suggests that  level of Cyclin D1 and Ki 67 expressions did not have any 
association with both MGUS and MM groups (p-value=1.000 and p-value=0.186). 
Cyclin D1 was positive in 22.4% of MM cases (13 out of 58) and 17.6% of MGUS (3 
from 17). As shown in Table.11, 8 cases of MM (13.8%) were positive for 
Ki67staining while MGUS cases were entirely negative for Ki67staining.  
The survival analysis in MM patients did not indicate any association between Cyclin 
D1 or Ki67 expression and MM prognosis (Cyclin D1 log-rank p-value=0.16 and 
Ki67 long rank p-value=0.55). Cyclin D1 positive cases had a median overall survival 
of 40 months versus 84 months in negative cases (Figure 26A). Moreover, the median 




reached, more than half of patients were died during the follow up, although the 
median overall survival for this entire cohort study was 79.5 months (Figure 26B).   
 




















Figure 26 :A) Median overall survival was 40 months versus 84 months in Cyclin D1 
positive MM cases B) Median overall survival of Ki67 positive patients was not 







Table 11: The number of positive cases, p-value, and log–rank p-value (survival 
anaylsis) for different markers expressions in MGUS and MM groups. 
 
Marker MM MGUS Total case P-Value Log-rank 
P-value 




























0/17 (0%) 9/75 (12%) 0.109 0.0003 
 
 
3.4 Evaluation of p16 and cleaved caspase 3 (CC3) expression 
3.4.1 Staining pattern 
The cleaved caspase 3 (CC3) and p16 have nuclear and cytoplasm staining that is 
shown as red color in figure 26. On the other hand, brown color in the membrane of 
cells demonstrated the CD138 (plasma cell marker) staining (figure 27, 28). Therefore 
the positive plasma cells for p16 and CC3 had a combination of red color in either 
nucleus or cytoplasm (p16 or CC3) and brown color in membrane (CD138)(Figure 
27,28). In addition, the endothelial cells are occasionally positive for p16 and were 
used as positive internal control.  In this study, CC3 or p16≥1% was considered as 






Figure 27: A) Positive p16 expression in MM case (40X manification) B) MM 






Figure 27: C) MGUS case with negative expression of p16 
 
 










Figure 28: B) expression of CC3 in negative CC3 case of MM. There are a few 
apoptotic cells with apoptotic bodies which is pointed C) MGUS sample with 






3.4.2 p16 expression in MGUS and MM 
The results were shown in Table 11 suggests that the p16 expression level was not 
significantly different in MM and MGUS patients (p-value=0.099). one quarter of 
MM patients (25.9%, 15 out of 58) expressed the p16 and one case of MGUS (5.9%) 
was p16 positive in this study. In addition, the survival analysis was not able to find 
any association between MM prognosis and p16 expression (log-rank p-value=0.80). 
The median overall survival for p16 positive cases was not reached, while the median 
overall survival of entire cohort was 79.5 months (Figure 29).    










Figure 29: The overall survival of p16 positive cases was not reached versus 79.5 
months. 
 
3.4.3 Cleaved Caspase 3 expression in MM and MGUS 
As it was demonstrated in table 11, expression of CC3 significantly and positively 
increased in MM group compare to MGUS group (p-value=0.030). All positive CC3 
staining (18.7%, 14 from 75 cases) had MM diagnosis which was one quarter (24.1%) 
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of MM patients. In addition, MGUS samples were completely negative for CC3 
staining (table 2). However, this study did not establish any association between CC3 
expression and MM prognosis (log-rank p-value=0.84). The median overall survival 














Figure 30: The median overall survival of CC3 positive cases was 40 months versus 











4.1 DDR and OIS barriers in MGUS and MM 
DNA damage response (DDR) and oncogene-induced senescence (OIS) are two 
important tumorigenic barriers in some types of premalignant tissues such as lung, 
skin, bladder, prostate, colon, and they prevent formation of cancer in these types of 
tissues. In these studies, expression of DDR and OIS markers increased in 
premalignant tissues and then disappeared or decreased in malignant tissues[30‐32]‐
31]‐31,[34][33]33[35][34]‐34,[49]. Therefore, some events that affect inactivation of OIS 
and DDR in premalignant tissues will accelerate a cancer formation. The role of these 
two barriers was not previously evaluated in monoclonal gammopathies, so we 
focused on these tumorgenesis barriers in MGUS as a premalignant state of plasma 
cell dyscrasia, and myeloma as malignant tumor.   
Different types of cell stress can cause the DNA double strand breaks (DSB) that are 
able to activate checkpoint proteins such as ATM, ATR, CHK2, and CHK1. 
Activation of these checkpoints leads to the activation of downstream tumor 
suppressors such as p53, and Rb, which result in G1 or G2 arrest and then senescence 
or apoptosis. Also, activation of oncogenes in some tissues may result in senescence, 
known as oncogene-induced senescence (OIS) and activate the Rb and ARF proteins 
that arrest cell cycle in G1 or G2 phase. Thus, investigating the phenotypic markers of 
senescence (p16) or apoptosis (cleaved caspase 3, CC3) was the first step we took in 
studying the role of DDR or OIS in this study. We planned to examine the upstream 
markers of DDR or OIS to determine if we would find enough evidences for 
activation of apoptosis or senescence in MGUS samples as our premalignant tumor 
model compared to malignant myeloma. 
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To investigate the two tumorigenic barriers in MGUS and MM samples, phenotypic 
markers of apoptosis (CC3) and senescence (p16) were evaluated. CC3 was selected 
as a phenotypic marker of apoptosis, as it is a key downstream intermediate of 
intrinsic and extrinsic apoptosis pathways and for practical considerations, its 
antibody is widely available and applicable for IHC analysis on paraffin-embedded 
tissues. In addition, p16 was selected as a senescence marker because determination 
of β-galactosidase activity (phenotypic markers of senescence) in paraffin-embedded 
archival tissues is not possible and also p16 is a known senescence marker widely 
used in IHC studies. From our results, the CC3 expression was interestingly increased 
in MM samples compared to MGUS samples, but the p16 expression did not show 
any significant changes in these two groups. Based on our findings, apoptosis was 
more evident in myeloma samples than in MGUS samples, but senescence was not 
seen as an active phenomenon in MGUS samples. We were thus not able to find the 
primary evidence of DDR or OIS activation in the premalignant tumor of MGUS with 
inactivation of these barriers in malignant myeloma, and our hypothesis was not 
proven for this type of hematological malignancy.  
Besides exploring CC3 and p16 expression, ki67, Cyclin D1, p53, Bax, and Bcl-2 
expressions were also evaluated in our study. The p53 tumor suppressor is involved in 
both the DDR and OIS pathways which can trigger the apoptosis by activation of the 
BH3 family and can also trigger senescence by activation of p21. Based on our 
results, the p53 expression did not vary between MGUS and MM samples. This result 
also supports our previous results for CC3 and p16 expressions and demonstrated that 
the inactivation of the DDR and/or OIS barriers is not a transformation-linked event 
in MM tumorigenesis and development.  
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Moreover, Bax and Bcl-2 as pro-apoptotic and anti-apoptotic proteins were assessed 
in this project, given that activation of the DDR pathway will result in activation of 
the BH3 family and thereby increase apoptosis in premalignant samples. Interestingly, 
we found that both Bax and Bcl-2 expressions were low in MGUS samples; however, 
their expressions were significantly increased in MM samples. Overexpression of Bax 
is in accordance with our previous results for CC3 expression which also displayed an 
increased level of apoptosis in myeloma samples compared to MGUS. Indeed, Bax 
overexpression was in the malignant plasma cells of the myeloma samples and was 
not evident in the plasma cells of the MGUS samples in our study, lends further 
crapulence to the concept that the DDR pathway is not an important barrier in MGUS 
during the malignant transformation process. 
The low expression of Ki67 (13.8%) that we found in the myeloma samples was not 
significantly different from that in the MGUS samples. Besides, our study suggests 
that Cyclin D1 was also not associated with transformation of MGUS to MM, because 
its expression level did not drastically change from MGUS to MM samples in double 
staining IHC. Cyclin D1 is involved in inactivation of Rb and progression of cell 
cycle from G1 to S phase. Thus, overexpression of Cyclin D1 might have prevented 
the cells from undergoing G1 arrest or senescence.  However, whilst Cyclin D1 
expression did not differ significantly between the MGUS and MM samples we 
analyzed, its expression level increased in both MGUS and MM samples, which can 
arguably be explained as the overexpression of Cyclin D1 being an early tumorigenic 
event. Furthermore, the observation of Cyclin D1 overexpression in some MGUS 
cases may be part of the reason why senescence is not stimulated in MGUS, since the 
Rb protein, a key molecule in senescence, might be inactivated by overexpression of 
Cyclin D1. Therefore, the Cyclin D1 expression finding can indirectly support 
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inactivation of senescence in MGUS samples and is consistent with our results for 
CC3, p16, p53 and Bax expression.  
We found that DDR and OIS are not important tumorigenesis barriers in MGUS; so, 
other genetic abnormalities or dysfunction would be responsible for the transition of 
MGUS to MM. Our study suffers from several limitations. Our MGUS sample size 
was limited to 17 cases only and also we did not have serial bone marrow biopsies of 
patients with history of MGUS that progressed to myeloma during their follow up. 
Thus, we could not demonstrate the occurrence of inactivation of DDR and OIS in the 
MGUS premalignant tumors. Indeed, we would have to collect serial bone marrow 
biopsy of MGUS patients, who developed the MM disease during the time, and then 
examine OIS and DDR markers again in a much bigger study.  
 
4.2 Individual marker evaluation in MM and MGUS 
4.2.1 p53 expression 
In this study, nine cases of MM (15.5%) were positive for p53 staining, showing a 
low rate of p53 mutation in myeloma. However, all MGUS cases were negative for 
p53 in double staining. The positive p53 staining in IHC indicates that p53 mutation 
occurred, since the mutated and nonfunctional p53 protein would accumulate in tissue 
and would be stained by IHC. Our p53 result in myeloma was consistent with a recent 
IHC report suggesting that p53 mutation is low in both newly diagnosed MM and 
relapse/refractory MM (4% and 20% respectively) [50]. In addition, our survival 
analysis of myeloma patients showed that there is significant association between 
short overall survival of myeloma patients (4.4 months) and p53 expression in bone 
marrow samples. Another study reported a low rate of p53 mutation (3%) in 268 
myeloma patients by applying FISH and PCR methods and also described the poor 
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survival in patients with p53 mutation for the first time in multiple myeloma [51]. Our 
findings of low p53 expression in double staining IHC of myeloma samples and also 
short survival of these myeloma patients were consistent with the low p53 mutation 
and very poor survival of mutated p53 myeloma patients in the above-mentioned 
study by Chng WJ et al [51]. 
In conclusion, although p53 staining appears to be a rare occurrence in newly 
diagnosed myeloma patients, its presence gives a significantly worse overall survival 
in these patients compared to patients with negative p53 staining. So, the p53 
expression in IHC is an independent poor prognostic factor in myeloma patients.  
 
4.2.2 Bax and Bcl-2 expressions 
Expression of Bax and Bcl-2 were remarkably increased in myeloma samples 
compared to MGUS group. Overexpression of Bax and Bcl-2 were found in 65.5% 
and 76% of MM patients respectively, whilst approximately 17% and 11% of MGUS 
patients showed overexpression of Bax and Bcl-2. In addition, there was a noteworthy 
association between short survival of MM patients and Bcl-2 overexpression in our 
study, but the level of Bax expression had no bearing on survival in myeloma patients. 
Bcl-2 is normally expressed in follicular lymphomas carrying the t(14;18) 
chromosomal translocation, but is also expressed in many lymphomas without Bcl-2 
rearrangement. Cristina Largo et al. and Luigia Lombardi et al. reported the 
overexpression of Bcl-2 and amplification of this gene in myeloma cell lines by 
applying fluorescence in situ hybridization (FISH), quantitative real-time PCR (q-
PCR) and comparative genomic hybridization (CGH) methods [52,53]. In addition, 
one study reported the Bcl-2 overexpression in MM compared to MGUS and reactive 
plasmacytoma, findings that are consistent with our results [54]. Indeed, the Bcl-2 
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overexpression is an early tumorigenic event, as Bcl-2 expression is increased from 
normal plasma cells to MGUS and also increased from MGUS to MM. Our Bcl-2 
expression result might have a therapeutic application in the near future, as some Bcl-
2 antagonists such as Genasense, TW-37, obatoclax and ABT-263 are now in clinical 
trial as new drugs in cancer treatment. However, ABT-737, a new antagonist of Bcl-2 
family, has monotherapy toxicity to lymphoma and leukemia, and at higher 
concentrations, has been shown to induce apoptosis in multiple myeloma cell lines in 
in vitro studies. ABT-737 can mimic the BH3 domain of the BAD molecule and can 
bind to Bcl-2, Bcl-xL, and Bcl-w, inhibiting the functions of these anti-apoptotic 
proteins [55].  
The overexpression of Bax and Bcl-2 in our current study is consistent with the work 
of Renner S et al. that showed increased Bax and Bcl-2 expression in 58 MM patients 
compared to 29 MGUS/smoldering myeloma patients and also 17 reactive 
plasmacytosis [56]. Furthermore, they demonstrated that myeloma patients with 
extremely low Bax expression had significantly increased survival, but they were not 
able to find any correlation between Bcl-2 expression and survival. Our survival 
results for Bax and Bcl-2 overexpression were completely in contrast with their 
findings, as we did not observe any correlation between Bax and survival of myeloma 
patients and we found instead a significant correlation between Bcl-2 overexpression 
and short survival in myeloma patients. We believe the double staining IHC results 
we reported are probably more accurate than those obtained from single staining IHC. 
Bax staining has been shown for other normal bone marrow cells such as erythroid, 
megakaryocytic, and lymphocyte which can produce a false positive result of Bax 
expression in single staining and thus affect correlation of Bax expression with overall 
survival of patients. In addition, our contrasting results with those of the Renner et al 
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study [13] may be partly related to differences inherent in the samples that were from 
two diverse ethnic populations. Also, other confounder factors such as new 
chemotherapeutic treatments may prolong the survival of our cohort patients and then 
may affect the results. In conclusion, more studies are needed to investigate the 
association of Bax overexpression and survival in myeloma, because there is just one 
report beside our study regarding Bax overexpression and overall survival of 
myeloma patients. 
“ The role of Bax overexpression in myeloma is unknown, because it is a pro-
apoptotic protein and should not be highly expressed in cancer. Recently, the role of 
Bax in plasma cell apoptosis was investigated by Pelletier et al [57]. They found that 
plasma cell apoptotic pathway is unique among other hematopoietic cells, 
as both the death receptor (extrinsic pathway) and the mitochondria (intrinsic 
pathway) do not play a central role. In fact, plasma cell apoptosis is started 
by the activation of Bax at the endoplasmic reticulum (ER) membrane 
and the subsequent activation of the ER-associated caspase-4 that occurs before 
release of apoptotic factors from the mitochondria [57]. The overexpression of Bax 
and increased level of the CC3 apoptotic marker in our cohort study may be 
consistent with activation of apoptosis by activation of Bax in the ER. The intrinsic 
pathway of apoptosis might be inhibited by overexpression of Bcl-2 in our myeloma 
samples, but overexpression of Bax in our cohort patients may also activate the ER 
apoptosis pathway and may then have increased the level of CC3 in these myeloma 
patients.       
The correlation of Bcl-2 overexpression and survival of myeloma patients is not well 
established. In this current study, we reported the positive association of Bcl-2 
overexpression and short survival of myeloma patients for the first time. However, 
three other studies were not able to show any relationship between Bcl-2 
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overexpression and survival of myeloma patients [54]-[56]. On the other hand, Ong F 
et al. reported a long survival in 27 myeloma patients with increased Bcl-2 expression 
that were in contrast to previously reported studies. A reason for the controversial 
result of Ong F et al. with our study might be related to their limited sample size (27 
patients)[58]. 
Although the Bax and Bcl-2 expressions increased in MM compared to MGUS, the 
Bcl-2/Bax ratio did not vary from MGUS samples to MM samples. It is possible that 
increased expression of either Bax or Bcl-2 causes the increased expression of another 
one, because these two proteins have balanced expression in mitochondrial 
membrane. Moreover, it is possible that various factors independently influence the 
overexpression of Bax and Bcl-2, but the Bcl-2/Bax ratio may not reflect any changes.  
 
4.2.3 Cleaved Caspase 3 expression 
The expression of cleaved caspase3 (CC3) as a phenotypic marker of apoptosis was 
investigated in newly diagnosed myeloma and MGUS patients for the first time. 
While CC3 was not expressed in MGUS patients, one third of myeloma patients 
expressed this marker and showed significant difference between MM and MGUS. 
However, CC3 mean expression was low (9 ± 3) in myeloma, which can explain a 
low rate of apoptosis in malignant plasma cells. Moreover, overall survival of 
myeloma patients in the CC3-positive expression group did not significantly differ 
from that in the CC3-negative group.  
Our study for CC3 is worthy of special mention for several reasons. Firstly, apoptosis 
was evaluated in newly diagnosed myeloma patients for the first time and also a low 
rate of apoptosis was found in malignant plasma cells. Secondly, there had been no 
previous reports of apoptosis and survival in myeloma patients and we were the first 
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to evaluate this issue for the first time. Thirdly, we used the double staining IHC, 
which is a powerful method to distinguish the expression of selected markers of 
interest in plasma cells by applying two antibodies and two colors in one slide that 
makes scoring of protein expression more accurate and precise.  
In hyperproliferative cancers, the apoptosis index may be high due to several reasons. 
However, increased level of apoptosis in myeloma samples compared to MGUS may 
not be accounted by an increased level of proliferation, as MM is a hypoproliferative 
malignancy and 75% of positive CC3 cases did not express Ki67 in this study. In fact, 
the role of CC3 and Bax overexpression are not known in myeloma and further study 
are needed to determine the roles of these two proteins in MM pathogenesis.  
Apoptosis in myeloma is executed via extrinsic and intrinsic pathways that lead to 
activation of caspases. When the apoptosis triggers either by the intrinsic or the 
extrinsic pathway, caspase 3 will be cleaved at Asp175 (cleaved caspase 3, CC3). The 
majority of chemotherapeutic drugs in MM act via a mitochondrial pathway that 
affects pro- and anti-apoptotic Bcl-2 family [59]. However, drug resistance in 
myeloma is more related to the extrinsic pathway and overexpression of TRAIL 
decoy receptors such as Apo-2L and DcR2. Agonist antibodies for TRAIL receptors 
have been reported to induce apoptosis in myeloma cells and were able to bypass the 
inhibition of TRAIL-induced apoptosis [60]. In addition, a recent study revealed that 
activation of Bax in the reticulum endoplasmic membrane initiates apoptosis and 
plays a central role in plasma cell apoptosis. The study also showed that death 
receptor and mitochondria did not have critical roles in initiation of PC apoptosis [57]. 
In conclusion, mechanisms of apoptosis in normal and malignant plasma cells are not 
well known and further studies are needed to investigate the underlying mechanisms 
of apoptosis in MM.  
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4.2.4 p16 expression 
Most somatic cells, unlike germ cells and certain stem cells, stop dividing after 
restricted cell divisions in culture and go into a phase termed cellular senescence. 
However, recent studies suggested that the activation of cellular senescence takes 
place in vivo and plays an important role in tumor suppression, vascular disease, 
fibrosis, and aging. Activation of oncogenes can lead to oncogene-induced senescence 
and activate the p16/Rb pathway. In vivo evidence suggests that the self-renewing 
stem cells in higher eukaryotes on progressive ageing, become senescent due to p16 
overexpression. In addition, Ito et al. showed that self-renewal of hematopoietic stem 
cells is harshly damaged because of increased ROS in ATM knockout mice, resulting 
in the up-regulation of p16 and increased senescence in hematopoietic stem cells[61]. 
Therefore, p16 is known as an in vivo senescent marker and down regulation of p16 is 
expected in a variety of cancers [62‐65]. 
Based on our data, expression of p16 was not considerably altered from MGUS to 
MM samples. Also, one quarter of myeloma patients expressed p16 and the mean 
ratio (4.05 ± 1.8) was low in positive cases. However, one case of MGUS expressed 
p16. Our result is in agreement with the study of Urashima,M et al. that showed high 
expression of p16 in eight myeloma patients by immunoprecipitation and western 
immunobloting methods. While p16 methylation did not affect protein expression of 
p16, the majority of studies focused on comparing methylation of p16 in MGUS and 
MM patients in the last decade [42,66].  Our study is thus unique as the expression of 
p16 was not well established in both groups of MGUS and MM in previous reported 
studies. Besides, a recent study investigated the association of p16 expression and 
response to the Bortezomib therapy in 89 relapse/refractory myeloma by IHC and 
found that patients with p16 expression had a poor response to Bortezomib [67]. 
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However, they used relapse/refractor myeloma patients and they did not evaluate p16 
expression in MGUS or newly diagnosed MM patients.  
Our survival analysis data suggested that there was no association between p16 and 
prolonged or short survival of myeloma patients. This is the first time that p16 
expression as a prognostication indicator of myeloma patients was examined. Indeed, 
many studies had examined the correlation between p16 methylation and survival of 
myeloma patients [68‐70]. But, there is no report about p16 protein expression and 
survival in previous studies. A comprehensive study on 561 monoclonal 
gammopathies had revealed that p16 methylation did not affect the p16 RNA 
expression and also did not associate with any poor or better prognosis in myeloma 
patients. The result of RNA expression and survival in the Gonzalez-paz-led study is 
consistent with our protein level of p16 result[42].  
Although p16 expression did not significantly differ in both MGUS and MM, it was 
expressed in myeloma patients more than in MGUS patients. This result is in contrast 
with our expectation for down regulation of p16 as a tumour suppression gene in 
cancers and its increased level in premalignant tissues as a senescent marker [62‐65]. 
In conclusion, further studies need to be done for understanding the exact role of p16 
in multiple myeloma pathogenesis.  
 
4.2.5 Cyclin D1 and Ki67 expressions 
The major regulatory events of mammalian cells such as proliferation and 
differentiation occur in the G1 phase of the cell cycle. Deregulation of G1 cycling and 
Cyclin-dependent kinases may influence cell cycle control and then result in increased 
oncogenesis. Cyclin D1 as a major regulatory of G1 phase of cell cycle forms a 
complex with CDK4/CDK6, whose activities are required for G1/S transition and 
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results in cell proliferation. In addition, p16 as an inhibitor of CDKs prevents 
phosphorylation of Rb and then results in senescence or cell cycle arrest; however, 
overexpression of Cyclin D1 might overcome the role of p16 in cell cycle arrest and 
thus result in proliferation or differentiation of cells [71]. 
Cyclin D1 is expressed in wide variety of human tissues; however, it is not expressed 
in lymphoid cells and myeloid lineages. Overexpression of Cyclin D1 in malignant 
plasma cells has been investigated in many studies and ranges from 17%-50% when 
evaluated by different methods such as reverse transcription-PCR (RT-PCR), 
Northern blotting, and immunohistochemistry [72‐76]. However, we chose to evaluate 
Cyclin D1 expression in MM and MGUS samples by applying the double staining 
IHC method, which is a precise technique to investigate two markers (such as CD138 
and CyclinD1) in the same slide. Based on our data, overexpression of Cyclin D1 did 
not significantly differ between MGUS and MM, since Cyclin D1 was expressed in 
22% of MM and 17% of MGUS patients. Our data is in agreement with other studies 
and suggest that deregulation of Cyclin D1 is an early pathogenesis event in 
monoclonal gammopathies and that this event alone is not enough to drive 
transformation of MGUS to symptomatic myeloma [50,77‐80].  
Furthermore, the prognostic significance of Cyclin D1 overexpression is still 
controversial. Several studies have reported that myeloma patients with either the 
t(11;14) or 11q abnormalities, and/or Cyclin D1 amplification, had a worse prognosis 
compared to the group without Cyclin D1 expression [71,72,81]. However, there are 
some studies reporting that patients carrying t(11;14) and treated with high-dose 
chemotherapy or conventional therapy had prolonged survival compared to patients 
without any genetic abnormalities [82,83]. In addition, Dawson et al. found that 
nucleus staining of Cyclin D1 in plasma cells was associated with a better response to 
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Bortezomib [67]. In contrast to prior studies, a recent study in 94 myeloma patients 
treated with Doxorubicin, Vincristine, Dexamethasone, and Thalidomide showed that 
Cyclin D1 negativity did not convey a poor overall survival or adverse progression-
free. They also reported a similar incidence of Cyclin D1 expression between newly 
diagnosed patients and relapse/refractory myeloma patients by double staining IHC 
[50]. In our survival analysis, we were also not able to find any correlation between 
Cyclin D1 expression and overall survival of myeloma patients. Moreover, our result 
is in agreement of other published data that showed overexpression of Cyclin D1 in 
27% of 59 myeloma patients and also they did not find any association between 
Cyclin D1 and overall survival of myeloma patients that is consistent with our result 
[78]. On the other hand, Cook JR et al. reported a longer overall survival in Cyclin D1 
positive cases (15 out of 20, 75%) myeloma patients. Their results are in contrast with 
our data, which might be related to the technique used and their small sample size (20 
cases) [84]. 
The proliferative activity of malignant plasma cells was measured with ki67 
expression in our samples. Ki67 was not expressed in any MGUS samples; however, 
it was positive in 13% of MM. In addition, Ki67 expression did not significantly 
change from MGUS to MM samples. In fact, myeloma is a hypoproliferative disease 
and ki67 expression is low in this malignancy [85,86]. We could not reveal any 
association between ki67 and Cyclin D1positive cases in our study. Thus, Cyclin D1 
overexpression does not influence higher proliferative activities in our study as well 
as other studies [76,87].  
In conclusion, Cyclin D1 overexpression is an early pathogenesis event in plasma cell 
malignancies and it is not associated with improved or adverse prognosis in myeloma 
patients. Cyclin D1 overexpression in MGUS samples might yet be another 
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supportive evidence of inactivation OIS barrier in MGUS, since Cyclin D1 up-

























Recent studies proposed that the DDR and OIS are two tumorigenic barriers in several 
solid tumors.  The researchers observed an increased level of DDR and OIS 
activations in premalignant tissues compared to malignant tissues. Activation of the 
OIS and DDR pathways in premalignant tissues can increase the level of senescence 
and apoptosis in these tissues. On the other hand, inactivation of these barriers will 
accelerate cancer formation and decrease the senescence and apoptosis in malignant 
tissues. Although several studies have focused on finding the transformation events in 
MGUS to MM, events or factors mediating this transformation are still unknown.  In 
this study, we had planned to document by experimental evidence the existence of 
DDR and OIS as critical events in the transition of MGUS to MM, and to further 
investigate the specific markers involved, if their roles are verified.  
The results of our study suggested that DDR and OIS are not important barriers of 
cancer development in multiple myeloma. In fact, the p16 expression as a phenotypic 
marker of senescence did not demonstrate significant changes between MGUS and 
MM samples. However, expression of CC3 as a phenotypic marker of apoptosis was 
unexpectedly increased in MM.  In contradiction to our proposed hypothesis, the 
phenotypic markers of senescence and apoptosis as the outcome of DDR and OIS 
activations were not augmented in MGUS compared to MM. 
Other pro- and anti-apoptotic markers as well as proliferation and cell cycle markers 
with their corresponding impacts on overall survival of MM were investigated in our 
study to find any association between senescence, apoptosis, and proliferation events 
in MGUS and MM. Bax and Bcl-2 overexpression were seen in MM samples 
compared to MGUS. Also, we demonstrated a positive association between BCl-2 
overexpression and short survival of newly diagnosed MM patients for the first time. 
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However, we were not able to find any correlation between prolonged overall survival 
of myeloma patients and Bax overexpression. Moreover, Cyclin D1, Ki67, and p16 
expressions did not significantly change when MGUS progressed to MM, and also 
their expressions were not associated with overall survival of MM patients.  Despite 
the fact that p53 expression did not vary between MGUS and MM samples, the data 
from the survival analysis showed a significant correlation between p53 expression 
and poor overall survival in MM patients. In conclusion, increased levels of selective 
apoptotic markers were found in MM compared to MGUS patients; however, the 
senescence and proliferation were not statistically significantly varied between these 
two groups of patients.  
Understanding of differential expression of various markers will provide significant 
insights into the biology of monoclonal gammopathies. More importantly, these 
insights may inform on chemo-preventive measures. Indeed, therapeutic targeting of 
various aspects of tumor suppressor genes such as reactivation of p53 or p16, and 
inhibition of anti-apoptotic Bcl-2, which have shown efficacy in variety of tumors, 











6. Future work 
To investigate the activation of DDR and OIS during the transformation of MGUS to 
MM, we would have to and indeed are planning to obtain serial samples of MGUS 
patients that progressed to MM during their follow up and examine DDR and OIS 
markers in all such serially collected samples. As noted throughout the Discussion 
chapter, additional MGUS bone marrow samples would be also be essential to arrive 
at a better understanding and conclusion of this critical transformation stage. In 
addition, more BM samples and clinical data of MM patients would strengthen the OS 
cure results.  
We had to use p16 as a senescence marker, since this antibody was applicable for 
paraffin-embedded tissues and also many studies used it as a senescence marker. 
However, β-galactosidase is probably a better phenotypic marker of senescence and 
but the kit reagents for this marker was not applicable for paraffin-embedded tissues. 
In future, we plan to collect fresh plasma cells from bone marrow of MGUS and MM 
patients and measure the β-galactosidase activity in these samples. Furthermore, a 
future step would be to study the causes behind Bax overexpression in MM and find 
the role of this pro-apoptotic protein in the pathogenesis of myeloma. It is a notable 
finding of our study that CC3 expression was significantly increased in MM samples, 
which suggest that the apoptotic index in MM patients is higher than that of MGUS 
samples. However, we did not investigate which apoptotic pathways (intrinsic or 
extrinsic) were exactly involved in the demonstrated increased level of CC3. A logical 
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The IHC technique generally includes the following steps: 
1. De-paraffinization of tissue sections mounted on coated slides.  
2. Antigen retrieval with methods available.  
3. Blocking of endogenous enzymes (which otherwise would react with IHC 
reagents giving false-positive results). Peroxidases, alkaline phosphatases, and 
biotin are examples of endogenous enzymes. This step is usually done by 3% 
hydrogenperoxide or with free avidin. 
4. Binding with primary antibody. 
5. Binding with secondary antibody. 
6. Applying detection methods such as avidin-biotin conjugates, peroxidase-
antiperoxidase methods, peroxidases complexes, or the more recently used 
polymer-labeling two-step method. 
7. Adding the chromogen substrate, usually DAB (3.3’-diaminobenzidine). 
8. Counterstaining, dehydrating, clearing, and cover-slipping the slide. 
A brief introduction of staining methods, antigen retrieval procedures, enzyme 
reaction, fixation of tissue and type of antibodies in IHC would help to better 
understanding of IHC concept. 
 
General double staining procedure 
1. Quench for endogenous peroxidase activity. 
2. Rinse and incubate for 3–5 minutes in wash buffer. (Incubate for 10* minutes with 
each reagent in Steps 3, 4, 8 and 9; repeats Step 2 after each step) 
3. First primary antibody incubation. 
4. First link antibody/peroxidase-conjugated polymer. 
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5. First substrate-chromogen incubate for 5–10 minutes. 
6. Rinse with distilled water. 
7. Incubate in double stain block reagent for 3 minutes. 
8. Second primary antibody incubation. 
9. Second link antibody/alkaline phosphatase conjugated polymer. 
10. Second substrate-chromogen incubates for 5–10 minutes. 
11. Rinse with distilled water. 
12. Counterstain, clear and coverslip. 
